<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">psvkhMSYnK5vNMZkcRw8czC</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2023000200304</article-id>
      <article-id pub-id-type="other">00304</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20220247</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo Original</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Estat&#237;sticas Cardiovasculares do Programa Boas Pr&#225;ticas em Cardiologia &#8211; Dados de um Hospital P&#250;blico Terci&#225;rio Brasileiro</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-8260-9212</contrib-id>
          <name>
            <surname>Passaglia</surname>
            <given-names>Luiz Guilherme</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica e Reda&#231;&#227;o do manuscrito</role>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9601-7189</contrib-id>
          <name>
            <surname>Cerqueira</surname>
            <given-names>Marina L&#237;rio Resende</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica e Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pires</surname>
            <given-names>Mariana Martins</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica e Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chagas</surname>
            <given-names>Lucas Vieira</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica e Reda&#231;&#227;o do manuscrito</role>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cunha</surname>
            <given-names>Carolina Teixeira</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodrigues</surname>
            <given-names>Erika Nunes de Oliveira</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Diniz</surname>
            <given-names>Fl&#225;via Mariana Mendes</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Darkiane Fernandes</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nogueira</surname>
            <given-names>Monique Rocha</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Braga</surname>
            <given-names>Gisia Teodoro</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taniguchi</surname>
            <given-names>F&#225;bio P.</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de financiamento</role>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Antonio Luiz Pinho</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <institution content-type="orgdiv2">Servi&#231;o de Cardiologia e Cirurgia Card&#237;aca</institution>
        <institution content-type="orgdiv1">Hospital das Cl&#237;nicas</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Minas Gerais &#8211; Servi&#231;o de Cardiologia e Cirurgia Card&#237;aca do Hospital das Cl&#237;nicas, Belo Horizonte, MG &#8211; Brasil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Minas Gerais &#8211; Faculdade de Medicina, Belo Horizonte, MG &#8211; Brasil</institution>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <institution content-type="orgdiv2">Equipe de Enfermagem</institution>
        <institution content-type="orgdiv1">Hospital das Cl&#237;nicas</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Minas Gerais &#8211; Equipe de Enfermagem do Hospital das Cl&#237;nicas, Belo Horizonte, MG &#8211; Brasil</institution>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <institution content-type="orgname">Hospital do Cora&#231;&#227;o</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital do Cora&#231;&#227;o (Hcor), S&#227;o Paulo, SP &#8211; Brasil</institution>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <institution content-type="orgdiv1">Departamento de Cl&#237;nica M&#233;dica</institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Minas Gerais &#8211; Departamento de Cl&#237;nica M&#233;dica da UFMG e Centro de Teless&#225;ude do Hospital das Cl&#237;nicas,Belo Horizonte, MG &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"> Correspond&#234;ncia: Luiz Guilherme Passaglia &#8226; Universidade Federal de Minas Gerais &#8211; Servi&#231;o de Cardiologia e CCV do HC-UFMG &#8211; Avenida Alfredo Balena, 110. CEP 30130-100, Santa Efig&#234;nia, Belo Horizonte, MG &#8211; Brasil E-mail: <email>lg.passaglia@uol.com.br</email> </corresp>
        <fn fn-type="conflict">
          <p>Potencial conflito de interesse</p>
          <p>N&#227;o h&#225; conflito com o presente artigo</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>10</day>
        <month>02</month>
        <year>2023</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2023</year>
      </pub-date>
      <volume>120</volume>
      <issue>2</issue>
      <elocation-id>e20220247</elocation-id>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>04</month>
          <year>2022</year>
        </date>
        <date date-type="rev-recd">
          <day>25</day>
          <month>09</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <title>Resumo</title>
        <sec>
          <title>Fundamento</title>
          <p> O Programa Boas Pr&#225;ticas em Cardiologia &#233; uma iniciativa da Sociedade Brasileira de Cardiologia (SBC) destinada &#224; melhoria do cuidado cardiovascular nos hospitais p&#250;blicos brasileiros.</p>
        </sec>
        <sec>
          <title>Objetivos</title>
          <p> Descrever caracter&#237;sticas dos pacientes internados com S&#237;ndrome Coronariana Aguda (SCA) e Insufici&#234;ncia Card&#237;aca (IC) e avaliar os indicadores de desempenho alcan&#231;ados nos bra&#231;os (SCA e IC) em um hospital p&#250;blico terci&#225;rio, com uma meta pr&#233;-estabelecida de 85% de ader&#234;ncia &#224;s recomenda&#231;&#245;es da SBC.</p>
        </sec>
        <sec>
          <title>M&#233;todos</title>
          <p> Estudo do tipo transversal descritivo realizado por meio da coleta de dados de pacientes que estiveram internados entre maio de 2016 e setembro de 2019.</p>
        </sec>
        <sec>
          <title>Resultados</title>
          <p> Foram inclu&#237;dos 1036 pacientes, 273 pacientes no bra&#231;o IC e 763 no bra&#231;o SCA. A m&#233;dia de idade foi de 59,8 &#177; 12,0 anos na SCA e 57,0 &#177; 14,1 anos na IC, com predom&#237;nio do sexo masculino em ambos os grupos. Mais da metade dos pacientes n&#227;o tinham ensino fundamental completo e mais de 90% declararam renda mensal inferior a cinco sal&#225;rios-m&#237;nimos. Na SCA, predominou o diagn&#243;stico de SCA com supradesnivelamento do segmento ST (66,3%) e 2,9% dos pacientes foram a &#243;bito. Na IC, a etiologia mais comum foi a Doen&#231;a de Chagas (25,8%) e 17,9% dos pacientes foram a &#243;bito. Na avalia&#231;&#227;o dos indicadores de desempenho, nove dos 12 indicadores tiveram taxas de ader&#234;ncia acima de 85%.</p>
        </sec>
        <sec>
          <title>Conclus&#227;o</title>
          <p> Programas de qualidade s&#227;o essenciais &#224; melhoria do cuidado e os indicadores de desempenho do hospital apontam para uma boa ades&#227;o &#224;s diretrizes assistenciais da SBC, particularmente no bra&#231;o da SCA.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="pt">
        <kwd>Doen&#231;as Cardiovasculares</kwd>
        <kwd>S&#237;ndrome Coronariana Aguda</kwd>
        <kwd>Insufici&#234;ncia Card&#237;aca</kwd>
        <kwd>Melhoria de Qualidade</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>310790/2021-2</award-id>
        </award-group>
        <award-group>
          <funding-source>CNPq</funding-source>
          <award-id>465518/2014-1</award-id>
        </award-group>
        <award-group>
          <funding-source>FAPEMIG</funding-source>
          <award-id>PPM-00428-17</award-id>
        </award-group>
        <award-group>
          <funding-source>FAPEMIG</funding-source>
          <award-id>RED-00081-16</award-id>
        </award-group>
        <funding-statement>Fontes de financiamento: O presente estudo foi financiado pelo PROADI-SUS e American Heart Association. Dr Ribeiro &#233; financiando em parte pelo CNPq (310790/2021-2 e 465518/2014-1) e pela FAPEMIG (PPM-00428-17 e RED-00081-16).</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="14"/>
        <equation-count count="0"/>
        <ref-count count="20"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>As doen&#231;as cardiovasculares (DCV) constituem a principal causa de morte no mundo e uma das cinco principais causas de anos de vida saud&#225;veis perdidos.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> No Brasil, a s&#237;ndrome coronariana aguda (SCA) &#233; a principal condi&#231;&#227;o card&#237;aca que leva ao &#243;bito e a insufici&#234;ncia card&#237;aca (IC) a principal condi&#231;&#227;o card&#237;aca que leva &#224; interna&#231;&#227;o hospitalar.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>Organiza&#231;&#245;es nacionais e internacionais t&#234;m desenvolvido e disseminado orienta&#231;&#245;es por meio de diretrizes cl&#237;nicas para auxiliar os profissionais de sa&#250;de no manejo das DCV.<sup><xref ref-type="bibr" rid="B3">3</xref> - <xref ref-type="bibr" rid="B5">5</xref> </sup> Apesar de uma vasta publica&#231;&#227;o de terapias comprovadamente eficazes, a ades&#227;o &#224;s recomenda&#231;&#245;es dispon&#237;veis nas diretrizes ainda permanece abaixo do ideal,<sup><xref ref-type="bibr" rid="B6">6</xref></sup> particularmente nos hospitais brasileiros, como demonstram os Registros ACCEPT,<sup><xref ref-type="bibr" rid="B7">7</xref></sup> BRACE<sup><xref ref-type="bibr" rid="B8">8</xref></sup> e BREATHE.<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
      <p>Nesse contexto, programas de melhoria da qualidade assistencial foram desenvolvidos na tentativa de garantir um cuidado adequado aos pacientes com DCV. Nos Estados Unidos da Am&#233;rica, o Programa <italic>Get With the Guidelines (</italic> Programa <italic>GWTG)</italic> &#233; uma iniciativa criada pela <italic>American Heart Association (AHA)</italic> e pela <italic>American Stroke Association</italic> com a finalidade de melhorar a qualidade do atendimento hospitalar desses pacientes.<sup><xref ref-type="bibr" rid="B10">10</xref></sup> No Brasil, a Sociedade Brasileira de Cardiologia (SBC) e o Minist&#233;rio da Sa&#250;de, junto do AHA e em colabora&#231;&#227;o com o Hospital do Cora&#231;&#227;o de S&#227;o Paulo - Hcor criaram o Programa Boas Pr&#225;ticas em Cardiologia (Programa BPC). Esse programa tem a finalidade de avaliar a taxa de ades&#227;o &#224;s recomenda&#231;&#245;es das diretrizes da SBC, assim como avaliar o resultado da implementa&#231;&#227;o de um programa de qualidade nos desfechos cl&#237;nicos dos pacientes internados por DCV.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
      <p>Diante disso, o presente estudo tem como objetivo caracterizar dados da interna&#231;&#227;o de pacientes com SCA e IC, participantes do Programa BPC, em um hospital p&#250;blico terci&#225;rio brasileiro, assim como avaliar as taxas de ades&#227;o &#224;s terapias baseadas em evid&#234;ncias, determinadas pela SBC e definidas como indicadores de desempenho.</p>
    </sec>
    <sec sec-type="methods">
      <title>M&#233;todos</title>
      <p>O presente estudo &#233; do tipo transversal descritivo realizado por meio da coleta de dados de pacientes internados no Hospital das Cl&#237;nicas da Universidade Federal de Minas Gerais entre maio de 2016 e setembro de 2019 com diagn&#243;stico prim&#225;rio de IC ou SCA. Detalhes do desenho e fundamento do Programa BPC foram previamente publicados,<sup><xref ref-type="bibr" rid="B11">11</xref></sup> e os bra&#231;os realizados nesse hospital tiveram aprova&#231;&#227;o do Comit&#234; de &#201;tica M&#233;dica da Universidade Federal de Minas Gerais (N&#250;mero: 1.487.029 de 11/04/2016).</p>
      <sec>
        <title>Popula&#231;&#227;o</title>
        <p>Foram inclu&#237;dos pacientes com idade igual ou superior a 18 anos, admitidos com diagn&#243;stico prim&#225;rio de SCA (CID-10 c&#243;digos I20.0 a I21.9 e I22.0 a I22.9) ou IC (CID-10 c&#243;digos I50.0; I50.1 ou I50.9), independente de hist&#243;ria pr&#233;via dessas condi&#231;&#245;es. Os crit&#233;rios de exclus&#227;o foram:</p>
        <p>(A) Pacientes com SCA desencadeada por revasculariza&#231;&#227;o mioc&#225;rdica eletiva (interven&#231;&#227;o coron&#225;ria percut&#226;nea eletiva ou cirurgia de revasculariza&#231;&#227;o do mioc&#225;rdio) ou por procedimentos cir&#250;rgicos maiores, n&#227;o card&#237;acos, durante interna&#231;&#227;o hospitalar.</p>
        <p>(B) Pacientes com hist&#243;ria pr&#233;via de IC, mas que foram admitidos na sala de emerg&#234;ncia com diagn&#243;stico cl&#237;nico confirmado de dispneia por outras causas. Tamb&#233;m foram exclu&#237;dos pacientes com interna&#231;&#227;o por IC e com remo&#231;&#227;o planejada para outro estabelecimento ou planejamento de interna&#231;&#227;o hospitalar por menos de 24 horas.</p>
      </sec>
      <sec>
        <title>Coleta de Dados</title>
        <p>Ap&#243;s a triagem quanto aos crit&#233;rios de elegibilidade, os pacientes eram questionados se desejavam participar do programa BPC ainda durante a interna&#231;&#227;o, e o Termo de Consentimento Livre e Esclarecido foi assinado por todos os participantes antes da aloca&#231;&#227;o. A coleta dos dados foi realizada a partir do prontu&#225;rio m&#233;dico e de entrevista presencial e estruturada por uma equipe treinada, utilizando os formul&#225;rios desenvolvidos pelo Programa BPC.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
      </sec>
      <sec>
        <title>Desfechos</title>
        <p>O desfecho prim&#225;rio do Programa BPC foram as taxas de ades&#227;o da equipe assistencial aos indicadores de desempenho, que s&#227;o m&#233;tricas de qualidade determinadas a partir de recomenda&#231;&#245;es classe I das diretrizes da SBC e AHA, descritas em detalhes em publica&#231;&#227;o anterior<sup><xref ref-type="bibr" rid="B11">11</xref></sup> e no site do Programa BPC (http://www.cardiol.br/boaspraticasclinicas/).</p>
        <p>Os indicadores de desempenho no bra&#231;o de SCA foram (Suplemento 1):</p>
        <list list-type="order">
          <list-item>
            <p>Aspirina precoce;</p>
          </list-item>
          <list-item>
            <p>Terapia de reperfus&#227;o adequada (tempo porta-agulha e tempo porta-bal&#227;o);</p>
          </list-item>
          <list-item>
            <p>Aspirina na alta;</p>
          </list-item>
          <list-item>
            <p>Inibidor da Enzima de Convers&#227;o de Angiotensina (IECA) ou Bloqueador do Receptor de Angiotensina (BRA) na alta em pacientes com Fra&#231;&#227;o de Eje&#231;&#227;o do Ventr&#237;culo Esquerdo (FEVE) &lt; 45%;</p>
          </list-item>
          <list-item>
            <p>Betabloqueador na alta;</p>
          </list-item>
          <list-item>
            <p>Estatina na alta;</p>
          </list-item>
          <list-item>
            <p>Controle da Press&#227;o Arterial na alta;</p>
          </list-item>
          <list-item>
            <p>Aconselhamento para parar de fumar para tabagistas ativos na alta.</p>
          </list-item>
        </list>
        <p>Os indicadores de desempenho no bra&#231;o de IC foram ( <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-1.pdf">Suplemento 1</ext-link> ):</p>
        <list list-type="order">
          <list-item>
            <p>Avalia&#231;&#227;o da fun&#231;&#227;o ventricular esquerda pelo ecocardiograma;</p>
          </list-item>
          <list-item>
            <p>IECA ou BRA na alta;</p>
          </list-item>
          <list-item>
            <p>Betabloqueador na alta;</p>
          </list-item>
          <list-item>
            <p>Espironolactona na alta;</p>
          </list-item>
          <list-item>
            <p>Consulta p&#243;s-alta (acompanhamento ambulatorial pr&#233;-agendado na alta hospitalar).</p>
          </list-item>
        </list>
        <p>Para o programa BPC, foi estabelecido como meta um limiar m&#237;nimo de ader&#234;ncia de 85% para os indicadores de desempenho descritos acima com base em resultados pr&#233;vios do programa <italic>GWTG.</italic> <sup><xref ref-type="bibr" rid="B12">12</xref></sup></p>
      </sec>
      <sec>
        <title>An&#225;lise estat&#237;stica</title>
        <p>Por ser um estudo observacional descritivo com uma amostra de conveni&#234;ncia, n&#227;o foi realizado o c&#225;lculo amostral. As vari&#225;veis cont&#237;nuas foram resumidas como m&#233;dia e desvio padr&#227;o ou como mediana e primeiro e terceiro quartis (Q1, Q3) conforme resultado do teste de normalidade (Shapiro-Wilk), considerando o n&#237;vel de signific&#226;ncia de 5%. As vari&#225;veis categ&#243;ricas foram expressas como propor&#231;&#245;es. Para o denominador de cada an&#225;lise, foram considerados apenas os dados v&#225;lidos da vari&#225;vel coletada, excluindo, portanto, os pacientes com dados incompletos e os pacientes que apresentavam contraindica&#231;&#245;es ao uso dos medicamentos que comp&#245;em os indicadores de desempenho, registradas no prontu&#225;rio m&#233;dico. Os dados foram analisados com a utiliza&#231;&#227;o do programa SPSS para Windows, vers&#227;o 20.1 (IBM Corp, Armonk, NY, EUA).</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Resultados</title>
      <p>Neste estudo foram inclu&#237;dos 1036 pacientes, sendo 763 pacientes com diagn&#243;stico de SCA (&#8220;bra&#231;o de SCA&#8221;) e 273 pacientes com diagn&#243;stico de IC (&#8220;bra&#231;o de IC&#8221;). A m&#233;dia de idade foi de 59,8 &#177; 12,0 anos nos pacientes do bra&#231;o de SCA e 57,0 &#177; 14,1 anos nos pacientes do bra&#231;o de IC, com predom&#237;nio do sexo masculino em ambos.</p>
      <p>As principais comorbidades dos pacientes foram hipertens&#227;o, diabetes e dislipidemia. No bra&#231;o de IC houve uma grande propor&#231;&#227;o de pacientes com hipotireoidismo e outras doen&#231;as de base. Uma significativa parcela dos pacientes declarou tabagismo atual ou passado, com destaque para o tabagismo atual no bra&#231;o de SCA ( <xref ref-type="table" rid="t1">Tabela 1</xref> ).</p>
      <p>
        <table-wrap id="t1">
          <label>Tabela 1</label>
          <caption>
            <title>&#8211; Caracteriza&#231;&#227;o da amostra na admiss&#227;o hospitalar (dados gerais e hist&#243;rico m&#233;dico)</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left">Vari&#225;vel</th>
                <th align="left" style="font-weight:normal"> </th>
                <th>S&#237;ndrome Coronariana Aguda (763)</th>
                <th>Insufici&#234;ncia Card&#237;aca (273)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Idade, m&#177;dp*</td>
                <td> </td>
                <td align="center">59,8 &#177; 12,0</td>
                <td align="center">57,0 &#177; 14,1</td>
              </tr>
              <tr>
                <td>Sexo Feminino</td>
                <td> </td>
                <td align="center">225/763 (29,5%)</td>
                <td align="center">119/273 (43,6%)</td>
              </tr>
              <tr>
                <td rowspan="7">Comorbidades</td>
                <td align="center">Hipertens&#227;o arterial sist&#234;mica</td>
                <td align="center">497/633 (78,5%)</td>
                <td align="center">108/260 (41,5%)</td>
              </tr>
              <tr>
                <td align="center">Diabetes mellitus</td>
                <td align="center">220/633 (34,8%)</td>
                <td align="center">69/260 (26,5%)</td>
              </tr>
              <tr>
                <td align="center">Dislipidemia</td>
                <td align="center">171/633 (27,0%)</td>
                <td align="center">38/260 (14,6%)</td>
              </tr>
              <tr>
                <td align="center">Acidente vascular encef&#225;lico ou acidente isqu&#234;mico transit&#243;rio</td>
                <td align="center">49/633 (7,7%)</td>
                <td align="center">18/260 (12,3%)</td>
              </tr>
              <tr>
                <td align="center">Doen&#231;a arterial perif&#233;rica</td>
                <td align="center">38/633 (6,0%)</td>
                <td align="center">17/260 (6,5%)</td>
              </tr>
              <tr>
                <td align="center">Hipotireoidismo</td>
                <td align="center">35/633 (5,5%)</td>
                <td align="center">41/260 (15,8%)</td>
              </tr>
              <tr>
                <td align="center">Doen&#231;a pulmonar obstrutiva cr&#244;nica/asma</td>
                <td align="center">47/633 (7,4%)</td>
                <td align="center">29/260 (11,2%)</td>
              </tr>
              <tr>
                <td rowspan="6">Cardiopatia pr&#233;via</td>
                <td align="center">Doen&#231;a coronariana</td>
                <td align="center">162/633 (25,6%)</td>
                <td align="center">29/260 (11,2%)</td>
              </tr>
              <tr>
                <td align="center">Infarto agudo do mioc&#225;rdio</td>
                <td align="center">119/633 (18,8%)</td>
                <td align="center">44/260 (16,9%)</td>
              </tr>
              <tr>
                <td align="center">Insufici&#234;ncia card&#237;aca</td>
                <td align="center">30/633 (4,7%)</td>
                <td align="center">236/260 (90,8%)</td>
              </tr>
              <tr>
                <td align="center">Fibrila&#231;&#227;o ou Flutter atrial</td>
                <td align="center">21/633 (3,3%)</td>
                <td align="center">99/260 (38,1%)</td>
              </tr>
              <tr>
                <td align="center">Doen&#231;a valvar</td>
                <td align="center">8/633 (1,3%)</td>
                <td align="center">39/264 (15,2%)</td>
              </tr>
              <tr>
                <td align="center">Doen&#231;a de Chagas</td>
                <td align="center">6/633 (0,8%)</td>
                <td align="center">66/264 (25,8%)</td>
              </tr>
              <tr>
                <td rowspan="6">Procedimentos Cardiol&#243;gicos pr&#233;vios</td>
                <td align="center">Angioplastia coronariana</td>
                <td align="center">98/763 (12,8%)</td>
                <td align="center">31/273 (11,4%)</td>
              </tr>
              <tr>
                <td align="center">Cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica</td>
                <td align="center">39/763 (5,1%)</td>
                <td align="center">8/273 (2,9%)</td>
              </tr>
              <tr>
                <td align="center">Marcapasso</td>
                <td align="center">6/763 (0,8%)</td>
                <td align="center">43/273 (15,8%)</td>
              </tr>
              <tr>
                <td align="center">Ressincronizador</td>
                <td align="center">2/763 (0,3%)</td>
                <td align="center">4/273 (1,5%)</td>
              </tr>
              <tr>
                <td align="center">cardiodesfibrilador</td>
                <td align="center">5/763 (0,7%)</td>
                <td align="center">39/273 (14,3%)</td>
              </tr>
              <tr>
                <td align="center">Transplante card&#237;aco</td>
                <td align="center">-</td>
                <td align="center">9/273 (6,3%)</td>
              </tr>
              <tr>
                <td rowspan="4">Tabagismo</td>
                <td align="center">Total (atual e pr&#233;vio)</td>
                <td align="center">509/761 (66,8%)</td>
                <td align="center">139/266 (55,3%)</td>
              </tr>
              <tr>
                <td align="center">Atual</td>
                <td align="center">253/761 (33,2%)</td>
                <td align="center">21/266 (7,9%)</td>
              </tr>
              <tr>
                <td align="center">Pr&#233;vio</td>
                <td align="center">256/761 (33,6%)</td>
                <td align="center">118/266 (44,4%)</td>
              </tr>
              <tr>
                <td align="center">N&#227;o</td>
                <td align="center">252/761 (33,1%)</td>
                <td align="center">127/266 (47,7%)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN1">
              <p>
                <italic>* Vari&#225;vel apresentada como m&#233;dia &#177; desvio padr&#227;o (m&#177;dp).</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>Mais da metade dos pacientes inclu&#237;dos no estudo n&#227;o tinham ensino fundamental completo e mais de 90% declararam renda mensal inferior a cinco sal&#225;rios-m&#237;nimos ( <xref ref-type="table" rid="t2">Tabela 2</xref> ).</p>
      <p>
        <table-wrap id="t2">
          <label>Tabela 2</label>
          <caption>
            <title>&#8211; Caracteriza&#231;&#227;o das vari&#225;veis socioecon&#244;micas</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left">Vari&#225;vel</th>
                <th align="left" style="font-weight:normal"> </th>
                <th>S&#237;ndrome Coronariana Aguda (763)</th>
                <th>Insufici&#234;ncia Card&#237;aca (273)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="7">Grau de Escolaridade</td>
                <td align="center">N&#227;o alfabetizado</td>
                <td align="center">72/761 (9,5%)</td>
                <td align="center">29/268 (10,8%)</td>
              </tr>
              <tr>
                <td align="center">Fundamental incompleto</td>
                <td align="center">372/761 (48,9%)</td>
                <td align="center">127/268 (47,4%)</td>
              </tr>
              <tr>
                <td align="center">Fundamental completo</td>
                <td align="center">91/761 (12,0%)</td>
                <td align="center">38/268 (14,2%)</td>
              </tr>
              <tr>
                <td align="center">Ensino m&#233;dio incompleto</td>
                <td align="center">67/761 (8,8%)</td>
                <td align="center">12/268 (4,5%)</td>
              </tr>
              <tr>
                <td align="center">Ensino m&#233;dio completo</td>
                <td align="center">85/761 (11,2%)</td>
                <td align="center">52/268 (19,4%)</td>
              </tr>
              <tr>
                <td align="center">Ensino superior incompleto</td>
                <td align="center">34/761 (4,5%)</td>
                <td align="center">5/268 (1,9%)</td>
              </tr>
              <tr>
                <td align="center">Ensino superior completo</td>
                <td align="center">40/761 (5,3%)</td>
                <td align="center">5/268 (1,9%)</td>
              </tr>
              <tr>
                <td rowspan="5">Renda Familiar</td>
                <td align="center">&#8804; 1 sal&#225;rio-m&#237;nimo</td>
                <td align="center">192/761 (25,2%)</td>
                <td align="center">76/268 (28,4%)</td>
              </tr>
              <tr>
                <td align="center">&gt; 1 a &#8804; 2 sal&#225;rios-m&#237;nimos</td>
                <td align="center">276/761 (36,3%)</td>
                <td align="center">131/268 (48,9%)</td>
              </tr>
              <tr>
                <td align="center">&gt; 2 a &#8804; 5 sal&#225;rios-m&#237;nimos</td>
                <td align="center">226/761 (29,7%)</td>
                <td align="center">46/268 (17,2%)</td>
              </tr>
              <tr>
                <td align="center">&gt; 5 a &#8804; 10 sal&#225;rios-m&#237;nimos</td>
                <td align="center">47/761 (6,2%)</td>
                <td align="center">12/268 (4,5%)</td>
              </tr>
              <tr>
                <td align="center">&gt; 10 sal&#225;rios-m&#237;nimos</td>
                <td align="center">20/761 (2,6%)</td>
                <td align="center">3/268 (1,1%)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </p>
      <p>No bra&#231;o de SCA ( <xref ref-type="table" rid="t3">Tabela 3</xref> ), a maior parte dos pacientes foram admitidos em classifica&#231;&#227;o de Killip-Kimball I-II (81,6%) e mais de um ter&#231;o (37,4%) apresentou recorr&#234;ncia de dor tor&#225;cica nas primeiras 24 horas da interna&#231;&#227;o hospitalar. Predominou o diagn&#243;stico de infarto agudo do mioc&#225;rdio (IAM) com supradesnivelamento do segmento ST (66,3%), sendo que 42,9% desses pacientes foram trombolisados, 33,8% realizaram angioplastia prim&#225;ria e 23,3% n&#227;o foram submetidos a nenhuma terapia de reperfus&#227;o.</p>
      <p>
        <table-wrap id="t3">
          <label>Tabela 3</label>
          <caption>
            <title>&#8211; Caracteriza&#231;&#227;o dos pacientes com s&#237;ndrome coronariana aguda no momento da interna&#231;&#227;o</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <tbody>
              <tr>
                <td align="left" rowspan="3">Tipo de s&#237;ndrome coronariana aguda</td>
                <td align="center" colspan="2">Angina inst&#225;vel</td>
                <td align="center">94/758 (12,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">IAM sem supra de ST</td>
                <td align="center">156/758 (20,6%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">IAM com supra de ST</td>
                <td align="center">506/758 (66,7%)</td>
              </tr>
              <tr>
                <td align="left" rowspan="4">Classifica&#231;&#227;o de Killip-Kimball</td>
                <td align="center" colspan="2">Killip I</td>
                <td align="center">491/755 (65,0%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Killip II</td>
                <td align="center">125/755 (16,5%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Killip III</td>
                <td align="center">55/755 (7,2%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Killip IV</td>
                <td align="center">58/755 (7,7%)</td>
              </tr>
              <tr>
                <td align="left">Parada cardiorrespirat&#243;ria &#224; admiss&#227;o</td>
                <td align="center" colspan="2"> </td>
                <td align="center">59/759 (7,8%)</td>
              </tr>
              <tr>
                <td>Recorr&#234;ncia de dor nas primeiras 24h</td>
                <td align="center" colspan="2"> </td>
                <td align="center">220/589 (37,4%)</td>
              </tr>
              <tr>
                <td rowspan="5">Exames laboratoriais &#224; admiss&#227;o*</td>
                <td align="center" colspan="2">Creatinina, mg/dL - m&#177;dp</td>
                <td align="center">0,96 &#177; 0,2</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Colesterol Total, mg/dL - md (IIQ)</td>
                <td align="center">168 (140-202)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">LDL-C, mg/dL - md (IIQ)</td>
                <td align="center">98 (72-129)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">HDL-C, mg/dL - md (IIQ)</td>
                <td align="center">41 (34-49)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Triglicer&#237;deos, mg/dL - md (IIQ)</td>
                <td align="center">112 (76-170)</td>
              </tr>
              <tr>
                <td>Candidatos a reperfus&#227;o</td>
                <td> </td>
                <td> </td>
                <td align="center">506/757 (67,1%)</td>
              </tr>
              <tr>
                <td rowspan="4">Terapia de reperfus&#227;o qu&#237;mica</td>
                <td align="center" colspan="2">Trombol&#237;tico</td>
                <td align="center">217/506 (42,9%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="3">Tipo de Trombol&#237;tico</td>
                <td align="center">Estreptoquinase</td>
                <td align="center">1/217 (0,5%)</td>
              </tr>
              <tr>
                <td align="center">Alteplase</td>
                <td align="center">175/217 (80,6%)</td>
              </tr>
              <tr>
                <td align="center">N&#227;o documentado</td>
                <td align="center">41/217 (18,9%)</td>
              </tr>
              <tr>
                <td rowspan="4">Cineangiocoronariografia</td>
                <td align="center" colspan="2">Cineangiocoronariografia diagn&#243;stica</td>
                <td align="center">706/757 (93,3%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Realizado ICP do vaso culpado</td>
                <td align="center">495/756 (65,5%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">ICP prim&#225;ria</td>
                <td align="center">171/506 (33,8%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">ICP de resgate</td>
                <td align="center">84/495 (17,0%)</td>
              </tr>
              <tr>
                <td rowspan="6">Cineangiocoronariografia (localiza&#231;&#227;o das les&#245;es)</td>
                <td align="center" colspan="2">Sem les&#245;es</td>
                <td align="center">45/547 (8,6%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Univascular</td>
                <td align="center">150/547 (27,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Bivascular</td>
                <td align="center">145/547 (26,5%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Trivascular</td>
                <td align="center">207/547 (37,8%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Les&#227;o de TCE</td>
                <td align="center">21/547 (3,8%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Les&#227;o de DA proximal</td>
                <td align="center">187/547 (34,2%)</td>
              </tr>
              <tr>
                <td>Fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo, % - md (IIQ)*</td>
                <td> </td>
                <td> </td>
                <td align="center">54 (43-62)</td>
              </tr>
              <tr>
                <td>Cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica</td>
                <td> </td>
                <td> </td>
                <td align="center">43/763 (5,6%)</td>
              </tr>
              <tr>
                <td>N&#250;mero de dias em terapia intensiva &#8211; md (IIQ)*</td>
                <td> </td>
                <td> </td>
                <td align="center">4 (3-6)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN2">
              <p>
                <italic>DA: art&#233;ria descendente anterior; HDL-C: high-density lipoprotein cholesterol; IAM: infarto agudo do mioc&#225;rdio; ICP: interven&#231;&#227;o coron&#225;ria percut&#226;nea; LDL-C: low-density lipoprotein cholesterol; TCE: tronco de coron&#225;ria esquerda . * Vari&#225;veis apresentadas como m&#233;dia &#177; desvio padr&#227;o (m&#177;dp) ou mediana e 1&#186; e 3&#186; quartis [md (IIQ)].</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>No bra&#231;o de IC ( <xref ref-type="table" rid="t4">Tabela 4</xref> e <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-2.pdf">Suplemento 2</ext-link> ), as etiologias mais comuns foram a Doen&#231;a de Chagas (25,8%), a forma idiop&#225;tica (22,3%), a cardiopatia isqu&#234;mica (15,2%) e a doen&#231;a valvar (15,2%). A maioria dos pacientes internou em classe funcional de NYHA ( <italic>New York Heart Association</italic> ) III-IV (76,4%), com predom&#237;nio do perfil hemodin&#226;mico &#8220;quente e &#250;mido&#8221; (60,1%) &#224; admiss&#227;o. A FEVE m&#233;dia da amostra foi de 35,0% &#177; 9,0% e 50 pacientes (18,3%) foram encaminhados na mesma interna&#231;&#227;o hospitalar para a realiza&#231;&#227;o de transplante card&#237;aco. Ao longo da interna&#231;&#227;o, a dobutamina foi usada em algum momento em 53,9% dos pacientes, ou por admiss&#227;o j&#225; no perfil &#8220;frio&#8221;, ou por evolu&#231;&#227;o para sinais de baixo d&#233;bito card&#237;aco, assim como a furosemida venosa em &#8220;bolus&#8221; foi usada em 90,2% dos pacientes e a furosemida cont&#237;nua na bomba de infus&#227;o em 25,4%.</p>
      <p>
        <table-wrap id="t4">
          <label>Tabela 4</label>
          <caption>
            <title>&#8211; Caracteriza&#231;&#227;o dos pacientes com insufici&#234;ncia card&#237;aca no momento da interna&#231;&#227;o</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <tbody>
              <tr>
                <td rowspan="8">Etiologia da insufici&#234;ncia card&#237;aca</td>
                <td align="center">Chagas</td>
                <td align="center">66/264 (25,8%)</td>
              </tr>
              <tr>
                <td align="center">Idiop&#225;tica</td>
                <td align="center">57/264 (22,3%)</td>
              </tr>
              <tr>
                <td align="center">Isqu&#234;mica</td>
                <td align="center">39/264 (15,2%)</td>
              </tr>
              <tr>
                <td align="center">Valvar</td>
                <td align="center">39/264 (15,2%)</td>
              </tr>
              <tr>
                <td align="center">Hipertr&#243;fica</td>
                <td align="center">8/264 (3,1%)</td>
              </tr>
              <tr>
                <td align="center">Cardiotoxicidade</td>
                <td align="center">5/264 (2,0%)</td>
              </tr>
              <tr>
                <td align="center">Hipertensiva</td>
                <td align="center">5/264 (2,0%)</td>
              </tr>
              <tr>
                <td align="center">Outras</td>
                <td align="center">45/264 (17,0%)</td>
              </tr>
              <tr>
                <td rowspan="4">N&#250;mero de interna&#231;&#245;es nos &#250;ltimos 6 meses</td>
                <td align="center">0</td>
                <td align="center">44/184 (23,9%)</td>
              </tr>
              <tr>
                <td align="center">1</td>
                <td align="center">40/184 (21,7%)</td>
              </tr>
              <tr>
                <td align="center">2</td>
                <td align="center">42/184 (22,8%)</td>
              </tr>
              <tr>
                <td align="center">&gt; 2</td>
                <td align="center">58/184 (31,5%)</td>
              </tr>
              <tr>
                <td rowspan="4">Classe Funcional de <italic>New York Heart Association (NYHA)</italic></td>
                <td align="center">I</td>
                <td align="center">3/254 (1,2%)</td>
              </tr>
              <tr>
                <td align="center">II</td>
                <td align="center">16/254 (5,9%)</td>
              </tr>
              <tr>
                <td align="center">III</td>
                <td align="center">70/254 (27,6%)</td>
              </tr>
              <tr>
                <td align="center">IV</td>
                <td align="center">124/254 (48,8%)</td>
              </tr>
              <tr>
                <td rowspan="2">Paciente na fila do transplante card&#237;aco</td>
                <td align="center">Sim</td>
                <td align="center">70/259 (27%)</td>
              </tr>
              <tr>
                <td align="center">N&#227;o</td>
                <td align="center">189/259 (73%)</td>
              </tr>
              <tr>
                <td rowspan="4">Perfil hemodin&#226;mico</td>
                <td align="center">Quente e seco</td>
                <td align="center">8/253 (3,2%)</td>
              </tr>
              <tr>
                <td align="center">Quente e &#250;mido</td>
                <td align="center">152/253 (60,1%)</td>
              </tr>
              <tr>
                <td align="center">Frio e &#250;mido</td>
                <td align="center">62/253 (24,5%)</td>
              </tr>
              <tr>
                <td align="center">Frio e seco</td>
                <td align="center">8/253 (3,2%)</td>
              </tr>
              <tr>
                <td rowspan="7">Causa da descompensa&#231;&#227;o</td>
                <td align="center">N&#227;o ades&#227;o medicamentosa</td>
                <td align="center">23/273 (8,4%)</td>
              </tr>
              <tr>
                <td align="center">N&#227;o ades&#227;o alimentar ou h&#237;drica</td>
                <td align="center">11/273 (4,0%)</td>
              </tr>
              <tr>
                <td align="center">Hipertens&#227;o n&#227;o controlada</td>
                <td align="center">5/273 (1,8%)</td>
              </tr>
              <tr>
                <td align="center">Infec&#231;&#227;o</td>
                <td align="center">42/273 (15,4%)</td>
              </tr>
              <tr>
                <td align="center">Arritmia</td>
                <td align="center">46/273 (16,8%)</td>
              </tr>
              <tr>
                <td align="center">Descompensa&#231;&#227;o da doen&#231;a renal</td>
                <td align="center">11/273 (4,0%)</td>
              </tr>
              <tr>
                <td align="center">Isquemia ou S&#237;ndrome Coronariana Aguda</td>
                <td align="center">14/273 (5,1%)</td>
              </tr>
              <tr>
                <td rowspan="2">Dados do ecocardiograma*</td>
                <td align="center">Fra&#231;&#227;o de Eje&#231;&#227;o do Ventr&#237;culo Esquerdo, % - m&#177;dp</td>
                <td align="center">35,0 &#177; 9,0</td>
              </tr>
              <tr>
                <td align="center">Di&#226;metro do &#193;trio Esquerdo, mil&#237;metros - m&#177;dp</td>
                <td align="center">49,5 &#177; 9,0</td>
              </tr>
              <tr>
                <td rowspan="2">Outros dados da interna&#231;&#227;o</td>
                <td align="center">Profilaxia para Trombose Venosa Profunda</td>
                <td align="center">237/256 (92,6%)</td>
              </tr>
              <tr>
                <td align="center">Registro de peso (pelo menos 70% do per&#237;odo da interna&#231;&#227;o)</td>
                <td align="center">173/256 (67,8%)</td>
              </tr>
              <tr>
                <td rowspan="2">Suspens&#227;o do betabloqueador (se uso pr&#233;vio), na admiss&#227;o ou interna&#231;&#227;o</td>
                <td align="center">Sim</td>
                <td align="center">81/141 (57,4%)</td>
              </tr>
              <tr>
                <td align="center">N&#227;o</td>
                <td align="center">60/141 (42,6%)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN3">
              <p>
                <italic>* Dados completos dispon&#237;veis no sistema (denominador da vari&#225;vel) - dados do ecocardiograma (217 pacientes). Vari&#225;vel apresentada como m&#233;dia &#177; desvio padr&#227;o (m&#177;dp)</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>As <xref ref-type="table" rid="t5">Tabelas 5</xref> e <xref ref-type="table" rid="t6">6</xref> mostram os dados de mortalidade intra-hospitalar e dados da alta hospitalar. Foram a &#243;bito na interna&#231;&#227;o 2,9% dos pacientes no bra&#231;o de SCA e 17,9% dos pacientes no bra&#231;o IC.</p>
      <p>
        <table-wrap id="t5">
          <label>Tabela 5</label>
          <caption>
            <title>&#8211; Dados dos pacientes com s&#237;ndrome coronariana aguda no momento da alta</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" colspan="4" scope="col">&#211;bitos intra-hospitalar</th>
                <th scope="col">22/763 (2,9%)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="2" rowspan="12">Medicamentos na alta</td>
                <td align="center" colspan="2">&#193;cido acetilsalic&#237;lico</td>
                <td align="center">700/733 (95,5%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Inibidor da P2Y12</td>
                <td align="center">657/733 (89,6%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Anticoagulante</td>
                <td align="center">94/733 (12,8%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2" rowspan="1">Betabloqueador</td>
                <td align="center">616/657 (93,7%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2" rowspan="1"> </td>
                <td align="center">BB contraindicado em 76/733 (10,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2" rowspan="1">Inibidor da Enzima de Convers&#227;o de Angiotensina</td>
                <td align="center">439/596 (73,7%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2" rowspan="1"> </td>
                <td align="center">IECA contraindicado em 137/733 (18,6%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2" rowspan="1">Bloqueador do receptor de angiotensina (BRA)</td>
                <td align="center">142/635 (22,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2" rowspan="1"> </td>
                <td align="center">BRA contraindicado em 98/733 (13,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">Estatina</td>
                <td align="center">707/733 (96,5%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2" rowspan="2">Espironolactona</td>
                <td align="center">78/486 (16,0%)</td>
              </tr>
              <tr>
                <td align="center">Espironolactona contraindicada em 247/733 (33,7%)</td>
              </tr>
              <tr>
                <td colspan="2" rowspan="3">Dados cl&#237;nicos na alta*</td>
                <td align="center" colspan="2">PA sist&#243;lica, mmHg &#8211; md (IIQ)</td>
                <td align="center">113 (100-130)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">PA diast&#243;lica, mmHg &#8211; md (IIQ)</td>
                <td align="center">70 (60-80)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">FC, batimentos por minuto &#8211; md (IIQ)</td>
                <td align="center">68 (63-78)</td>
              </tr>
              <tr>
                <td rowspan="29">Orienta&#231;&#245;es</td>
                <td align="center" rowspan="4">Cessa&#231;&#227;o de Tabagismo<sup>&#8224;</sup></td>
                <td align="center" colspan="2">Sim</td>
                <td align="center">277/340 (81,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o</td>
                <td align="center">3/340 (0,9%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o se aplica</td>
                <td align="center">393/733 (53,6%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o documentado</td>
                <td align="center">60/340 (17,6%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="3">Mudan&#231;a de estilo de vida</td>
                <td align="center" colspan="2">Sim</td>
                <td align="center">670/733 (91,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o</td>
                <td align="center">16/733 (2,2%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o documentado</td>
                <td align="center">46/733 (6,3%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="4">Controle do peso</td>
                <td align="center" colspan="2">Sim</td>
                <td align="center">546/710 (76,9%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o</td>
                <td align="center">24/710 (3,3%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o se aplica</td>
                <td align="center">23/733 (3,1%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o documentado</td>
                <td align="center">140/710 (19,7%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="3">Exerc&#237;cio f&#237;sico</td>
                <td align="center" colspan="2">Sim</td>
                <td align="center">660/733 (90,0%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o</td>
                <td align="center">17/733 (2,3%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o documentado</td>
                <td align="center">56/733 (7,7%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="4">Referenciado &#224; Reabilita&#231;&#227;o<sup>&#8224;</sup></td>
                <td align="center" colspan="2">Sim</td>
                <td align="center">615/721 (85,2%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o</td>
                <td align="center">32/721 (4,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o se aplica</td>
                <td align="center">12/733 (1,6%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o documentado</td>
                <td align="center">74/721 (10,3%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="3">Uso dos medicamentos prescritos</td>
                <td align="center" colspan="2">Sim</td>
                <td align="center">677/733 (92,4%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o</td>
                <td align="center">9/733 (1,2%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o documentado</td>
                <td align="center">47/733 (6,4%)</td>
              </tr>
              <tr>
                <td align="center" rowspan="4">Retorno ambulatorial</td>
                <td align="center" colspan="2">Sim</td>
                <td align="center">717/733 (97,8%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o</td>
                <td align="center">4/733 (0,5%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o se aplica</td>
                <td align="center">0/733 (0,0%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2">N&#227;o documentado</td>
                <td align="center">12/733 (1,7%)</td>
              </tr>
              <tr>
                <td align="center" colspan="2" rowspan="4">Terapia anticoagulante<sup>&#8224;</sup></td>
                <td align="center">Sim</td>
                <td align="center">85/114 (74,6%)</td>
              </tr>
              <tr>
                <td align="center">N&#227;o</td>
                <td align="center">14/114 (12,3%)</td>
              </tr>
              <tr>
                <td align="center">N&#227;o se aplica</td>
                <td align="center">619/733 (84,4%)</td>
              </tr>
              <tr>
                <td align="center">N&#227;o documentado</td>
                <td align="center">15/114 (13,1%)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN4">
              <p>
                <italic>FC: frequ&#234;ncia card&#237;aca; PAD: press&#227;o arterial diast&#243;lica; PAS: press&#227;o arterial sist&#243;lica; AAS: &#225;cido acetilsalis&#237;lico. * Vari&#225;veis apresentadas como mediana e 1&#186; e 3&#186; quartis [md (IQQ)]. &#8224; C&#225;lculo feito em rela&#231;&#227;o aos pacientes em que se aplica o tipo de orienta&#231;&#227;o.</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>
        <table-wrap id="t6">
          <label>Tabela 6</label>
          <caption>
            <title>&#8211; Dados dos pacientes com insufici&#234;ncia card&#237;aca no momento da alta</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" style="font-weight:normal">&#211;bitos intra-hospitalar</th>
                <th align="left" style="font-weight:normal"> </th>
                <th align="left" style="font-weight:normal"> </th>
                <th style="font-weight:normal">49/273 (17,9%)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">Anticoagulante</td>
                <td align="center">93/206 (45,1%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">BB</td>
                <td align="center">136/145 (93,8%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">BB contraindicado em 61/206 (29,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">IECA</td>
                <td align="center">72/128 (56,2%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">IECA contraindicado em 78/206 (37,9%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">BRA</td>
                <td align="center">48/145 (33,1%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">BRA contraindicado em 61/206 (29,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">Hidralazina</td>
                <td align="center">27/206 (13,1%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">Nitrato</td>
                <td align="center">23/206 (11,2%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">Antiarr&#237;tmicos</td>
                <td align="center">30/206 (14,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">Digoxina</td>
                <td align="center">26/206 (12,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">Diur&#233;tico de Al&#231;a</td>
                <td align="center">156/206 (75,7%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">Diur&#233;tico Tiaz&#237;dico</td>
                <td align="center">26/206 (12,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">Espironolactona</td>
                <td align="center">88/124 (70,9%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">Espironolactona contraindicada em 82/206 (39,8%)</td>
              </tr>
              <tr>
                <td rowspan="3">Dados cl&#237;nicos na alta*</td>
                <td> </td>
                <td align="center">PAS, mmHg - m&#177;dp</td>
                <td align="center">107,1 &#177; 18,5</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">PAD, mmHg - m&#177;dp</td>
                <td align="center">67,3 &#177; 12,4</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">FC, batimentos por minuto - m&#177;dp</td>
                <td align="center">77,9 &#177; 14,2</td>
              </tr>
              <tr>
                <td>Orienta&#231;&#245;es</td>
                <td align="center">Cessa&#231;&#227;o de tabagismo <sup>&#8224;</sup></td>
                <td align="center">Sim</td>
                <td align="center">10/27 (37,0%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">17/27 (63,0%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o se aplica</td>
                <td align="center">180/207 (87,0%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">0/27 (0,0%)</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">Controle do peso</td>
                <td align="center">Sim</td>
                <td align="center">122/207 (58,9%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">8/207 (3,9%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">77/207 (37,2%)</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">Exerc&#237;cio f&#237;sico</td>
                <td align="center">Sim</td>
                <td align="center">119/206 (57,8%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">16/206 (7,8%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">71/206 (34,5%)</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">Referenciado &#224; reabilita&#231;&#227;o<sup>&#8224;</sup></td>
                <td align="center">Sim</td>
                <td align="center">138/196 (70,4%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">5/196 (2,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o se aplica</td>
                <td align="center">11/207 (5,3%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">53/196 (27,0%)</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">Uso dos medicamentos prescritos</td>
                <td align="center">Sim</td>
                <td align="center">180/206 (87,4%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">0/206 (0,0%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">26/206 (12,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">Aconselhamento em caso de piora dos sintomas</td>
                <td align="center">Sim</td>
                <td align="center">141/206 (68,4%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">3/206 (1,4%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">62/206 (30,1%)</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">Aconselhamento para vacina&#231;&#227;o (Influenza e Pneumococo)</td>
                <td align="center">Sim</td>
                <td align="center">57/207 (27,5%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">21/207 (10,1%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">129/207 (62,3%)</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">Retorno ambulatorial</td>
                <td align="center">Sim</td>
                <td align="center">202/207 (97,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">5/207 (2,4%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">4/207 (1,9%)</td>
              </tr>
              <tr>
                <td> </td>
                <td align="center">Orienta&#231;&#245;es sobre terapia anticoagulante<sup>&#8224;</sup></td>
                <td align="center">Sim</td>
                <td align="center">53/63 (84,1%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o</td>
                <td align="center">1/63 (1,6%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o se aplica</td>
                <td align="center">77/140 (55,0%)</td>
              </tr>
              <tr>
                <td> </td>
                <td> </td>
                <td align="center">N&#227;o documentado</td>
                <td align="center">9/63 (14,3%)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN5">
              <p>
                <italic>BB: betabloqueador; IECA: inibidor da enzima de convers&#227;o de angiotensina; BRA: bloqueador do receptor de angiotensina; FC: frequ&#234;ncia card&#237;aca; PAS: press&#227;o arterial sist&#243;lica; PAD: press&#227;o arterial diast&#243;lica; mmHg: mil&#237;metro de merc&#250;rio. * Vari&#225;veis apresentadas como m&#233;dia &#177; desvio padr&#227;o (m&#177;dp). &#8224; C&#225;lculo feito em rela&#231;&#227;o aos pacientes em que se aplica o tipo de orienta&#231;&#227;o.</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>O <xref ref-type="table" rid="t7">Quadro 1</xref> mostra os Indicadores de Desempenho analisados. &#201; importante destacar que o indicador de &#8220;terapia de reperfus&#227;o adequada (tempo porta-agulha e tempo porta-bal&#227;o)&#8221; n&#227;o foi avaliado uma vez que o Hospital das Cl&#237;nicas recebe pacientes referenciados de toda a rede p&#250;blica metropolitana com o diagn&#243;stico de SCA para a realiza&#231;&#227;o de cineangiocoronariografia, o que inviabiliza a contabilidade desses tempos. As taxas de ades&#227;o foram acima de 85% para seis dos sete indicadores analisados no bra&#231;o de SCA e apenas para tr&#234;s dos cinco indicadores no bra&#231;o de IC. A <xref ref-type="fig" rid="f01">Figura Central</xref> resume os dados principais do artigo.</p>
      <p>
        <table-wrap id="t7">
          <label>Quadro 1</label>
          <caption>
            <title>&#8211; Indicadores de desempenho na alta hospitalar</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" scope="col" style="font-weight:normal"> </th>
                <th colspan="2" scope="col">Indicadores de desempenho</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="7">S&#237;ndrome Coronariana Aguda*</td>
                <td align="center">Aspirina precoce</td>
                <td align="center">739/756 (99,1%)</td>
              </tr>
              <tr>
                <td align="center">Aspirina na alta hospitalar</td>
                <td align="center">700/733 (95,5%)</td>
              </tr>
              <tr>
                <td align="center">IECA ou BRA na alta hospitalar</td>
                <td align="center">581/635 (91,5%)</td>
              </tr>
              <tr>
                <td align="center">Betabloqueador na alta hospitalar</td>
                <td align="center">616/657 (93,7%)</td>
              </tr>
              <tr>
                <td align="center">Estatina na alta hospitalar</td>
                <td align="center">707/733 (96,5%)</td>
              </tr>
              <tr>
                <td align="center">Controle da press&#227;o arterial</td>
                <td align="center">489/570 (85,8%)</td>
              </tr>
              <tr>
                <td align="center">Aconselhamento para parar de fumar</td>
                <td align="center">277/340 (81,5%)</td>
              </tr>
              <tr>
                <td rowspan="5">Insufici&#234;ncia Card&#237;aca</td>
                <td align="center">Avalia&#231;&#227;o da fun&#231;&#227;o ventricular esquerda</td>
                <td align="center">242/243 (99,6%)</td>
              </tr>
              <tr>
                <td align="center">IECA ou BRA na alta hospitalar</td>
                <td align="center">120/145 (82,7%)</td>
              </tr>
              <tr>
                <td align="center">Betabloqueador na alta hospitalar</td>
                <td align="center">136/145 (93,8%)</td>
              </tr>
              <tr>
                <td align="center">Espironolactona na alta hospitalar</td>
                <td align="center">88/124 (70,9%)</td>
              </tr>
              <tr>
                <td align="center">Consulta p&#243;s-alta hospitalar</td>
                <td align="center">202/207 (97,6%)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN6">
              <p>
                <italic>IECA: inibidor da enzima de convers&#227;o de angiotensina; BRA: bloqueador do receptor de angiotensina. *Observa&#231;&#227;o: o indicador de &#8220;terapia de reperfus&#227;o adequada&#8221; n&#227;o foi avaliado, uma vez que o hospital &#233; refer&#234;ncia para angioplastia prim&#225;ria e todos os pacientes dessa amostra foram encaminhados ao servi&#231;o j&#225; com o diagn&#243;stico de SCA.</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>
        <fig id="f01">
          <label>Figura Central</label>
          <caption>
            <title>: Estat&#237;sticas Cardiovasculares do Programa Boas Pr&#225;ticas em Cardiologia &#8211; Dados de um Hospital P&#250;blico Terci&#225;rio Brasileiro</title>
          </caption>
          <attrib>
            <italic>IC: insufici&#234;ncia card&#237;aca; IECA: inibidor da enzima de convers&#227;o de angiotensina; BRA: bloqueador do receptor de angiotensina; SCA: s&#237;ndrome coronariana aguda; SBC: Sociedade Brasileira de Cardiogia.</italic>
          </attrib>
          <graphic xlink:href="1678-4170-abc-120-02-e20220247-20247-gf01.tif"/></fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>Discuss&#227;o</title>
      <p>Os dados publicados nesse estudo caracterizam os pacientes internados por SCA e IC em um hospital federal, p&#250;blico e terci&#225;rio, que possui todas as linhas de cuidado aos pacientes cardiopatas atendidos pelo Sistema &#218;nico de Sa&#250;de. Apesar da baixa renda e da alta taxa de pacientes n&#227;o completamente alfabetizados, assim como uma alta complexidade cl&#237;nica, essas condi&#231;&#245;es n&#227;o foram impeditivas para uma adequada ades&#227;o &#224;s terapias baseadas em evid&#234;ncia determinadas pela SBC, particularmente na linha de cuidado da SCA.</p>
      <p>No Brasil, a SBC liderou a constru&#231;&#227;o de registros cl&#237;nicos das DCV, incluindo o registro nacional de SCA (estudo ACCEPT).<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Dados preliminares indicaram uma alta taxa de mortalidade intra-hospitalar, assim como baixas taxas de prescri&#231;&#245;es de terapias comprovadamente eficazes em pacientes internados. Esses dados s&#227;o concordantes tamb&#233;m com o Registro BRACE (Brazilian Registry on Acute Coronary Syndromes).<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
      <p>Em compara&#231;&#227;o com esses dois registros,<sup><xref ref-type="bibr" rid="B7">7</xref> , <xref ref-type="bibr" rid="B8">8</xref> </sup> os pacientes internados com SCA no Hospital das Cl&#237;nicas s&#227;o um pouco mais jovens, mas com perfil semelhante de comorbidades, particularmente as altas taxas de hipertens&#227;o, diabetes e tabagismo. No entanto, duas importantes diferen&#231;as se fazem presente: em primeiro lugar, houve predom&#237;nio de IAM com supradesnivelamento do segmento ST, uma vez que o Hospital das Cl&#237;nicas &#233; um centro de refer&#234;ncia da rede para angioplastia prim&#225;ria; e em segundo lugar, os indicadores de desempenho aqui apresentados no bra&#231;o de SCA s&#227;o quantitativamente melhores em compara&#231;&#227;o a todos os indicadores avaliados na alta hospitalar no BRACE.</p>
      <p>Vale destacar que na cidade de Belo Horizonte, com o intuito de ampliar o acesso dos pacientes do Sistema &#218;nico de Sa&#250;de ao tratamento de SCA, foi implementada a linha de cuidado do IAM entre os anos de 2010 e 2011.<sup><xref ref-type="bibr" rid="B13">13</xref></sup> Nesse processo, a participa&#231;&#227;o do Hospital das Cl&#237;nicas sempre se destacou por meio do Centro de Telessa&#250;de, Unidade Coronariana, Servi&#231;o de Cirurgia Cardiovascular, Setor de Hemodin&#226;mica, leitos de enfermaria especificamente dedicados a esses pacientes, al&#233;m de ambulat&#243;rios para a continuidade do cuidado p&#243;s-alta hospitalar. Com isso, essa linha de cuidado j&#225; vinha sendo monitorada no hospital e, diante dos dados previamente publicados,<sup><xref ref-type="bibr" rid="B14">14</xref></sup> o processo de educa&#231;&#227;o continuada permitiu os resultados dos indicadores de desempenho apresentados no estudo atual.</p>
      <p>Outro registro nacional tamb&#233;m liderado pela SBC &#233; o Registro BREATHE,<sup><xref ref-type="bibr" rid="B9">9</xref></sup> da linha de cuidado da IC, que assim como para SCA encontrou uma baixa taxa de prescri&#231;&#227;o de medicamentos baseados na melhor evid&#234;ncia para essa doen&#231;a. Quando comparados os dados do presente estudo com os do Registro BREATHE, os pacientes do Hospital das Cl&#237;nicas apresentam diferen&#231;as em termos das principais etiologias da IC e da maior complexidade cl&#237;nica. Isso se caracteriza pela presen&#231;a de muitos pacientes em avalia&#231;&#227;o e/ou encaminhados para transplante card&#237;aco, pelo frequente uso de inotr&#243;picos e vasodilatador venoso, assim como pela maior taxa de mortalidade intra-hospitalar. An&#225;lise dos indicadores de desempenho desse bra&#231;o indica uma grande necessidade de melhorias na prescri&#231;&#227;o de alta e orienta&#231;&#245;es ao paciente com IC.</p>
      <p>Seguindo uma tend&#234;ncia mundial, os gastos com sa&#250;de p&#250;blica em nosso pa&#237;s t&#234;m sido crescentes,<sup><xref ref-type="bibr" rid="B15">15</xref></sup> e uma s&#233;rie de iniciativas podem ser desempenhadas com objetivo de melhorar a efici&#234;ncia do sistema, particularmente iniciativas de melhoria da qualidade assistencial prestada aos pacientes com DCV.<sup><xref ref-type="bibr" rid="B16">16</xref></sup> Foi com esse foco que a SBC criou o programa BPC<sup><xref ref-type="bibr" rid="B11">11</xref></sup> e o Hospital das Cl&#237;nicas implementou o programa em sua institui&#231;&#227;o. Nessa mesma linha, projetos como o uso de mensagens de texto por telefone celular para melhorar o controle dos fatores de risco cardiovasculares ap&#243;s alta hospitalar tamb&#233;m foram desenvolvidos no hospital.<sup><xref ref-type="bibr" rid="B17">17</xref> , <xref ref-type="bibr" rid="B18">18</xref> </sup> Dados do Programa <italic>GWTG</italic> j&#225; s&#227;o robustos e mostram que a ades&#227;o &#224;s diretrizes melhorou significativamente ao longo do tempo,<sup><xref ref-type="bibr" rid="B19">19</xref></sup> gerando benef&#237;cios cl&#237;nicos aos pacientes atendidos nas institui&#231;&#245;es ligadas a esse programa nos Estados Unidos da Am&#233;rica.<sup><xref ref-type="bibr" rid="B20">20</xref></sup> A SBC fortalece sua a&#231;&#227;o em prol de um melhor cuidado cardiovascular poss&#237;vel para todos os brasileiros.</p>
      <p>Os dados do programa BPC no Hospital das Cl&#237;nicas aqui apresentados possuem algumas limita&#231;&#245;es importantes. Em primeiro lugar, o n&#250;mero de dados faltantes foi elevado para algumas das vari&#225;veis, o que possivelmente interferiu na an&#225;lise dos resultados. Em segundo lugar, por ser um estudo com necessidade de assinatura de termo de consentimento do paciente ou seus familiares, a mortalidade intra-hospitalar pode estar subestimada, pois pacientes graves que faleceram antes da assinatura do referido termo podem estar exclu&#237;dos dessa amostra. Em terceiro lugar, a coleta de dados n&#227;o p&#244;de ser consecutiva ao longo de todo o per&#237;odo analisado, tanto devido a problemas relacionados &#224; equipe da institui&#231;&#227;o envolvida com o programa BPC como por pequenos per&#237;odos de interrup&#231;&#227;o do pr&#243;prio programa nacionalmente. Por fim, n&#227;o foi poss&#237;vel apresentar o seguimento de 30 dias e seis meses ap&#243;s alta hospitalar devido ao n&#250;mero extremamente pequeno de dados registrados em sua completude.</p>
      <p>Em contrapartida, a apresenta&#231;&#227;o de dados nacionais, confi&#225;veis e abrangentes sobre DCV &#233; uma etapa obrigat&#243;ria para a supera&#231;&#227;o das desigualdades e para a oferta do melhor cuidado cardiovascular poss&#237;vel para todos os brasileiros. Este estudo re&#250;ne informa&#231;&#245;es relevantes da SCA e IC de pacientes internados em um hospital terci&#225;rio do Sistema &#218;nico de Sa&#250;de, e ajuda a preencher uma lacuna do conhecimento na literatura brasileira sobre o assunto, passo importante no planejamento da pol&#237;tica de sa&#250;de no Brasil.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclus&#227;o</title>
      <p>A ades&#227;o aos programas de qualidade como o Programa BPC &#233; um passo essencial &#224; melhoria assistencial dos pacientes internados com SCA e IC. Os indicadores de desempenho alcan&#231;ados apontam para uma boa ades&#227;o &#224;s diretrizes assistenciais da SBC, particularmente na linha de cuidado da SCA.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Agradecimentos</title>
      <p>Agradecemos a Caio Felipe Pereira Massei, Fernanda Lima Prado, Hugo Luiz Barros Alves, Giovana Zoboli Semabukuro, Giovanna Ribas Passagli, Gustavo Couto Pereira da Silva, Lorena Michelin Santos de Angelis Dias, Lorhayne Kerley Capuchinho Scalioni, Lucas Nevez Vaz, Luiz Octavio Rodrigues Ferreira, Mariana Figueiredo Sim&#245;es, Melissa de Andrade, Shaline Braga, Stephanie Kneipp, Tha&#237;s Souza, Warlenn Molendolff Silva. Todos os nomes descritos acima estiveram em algum momento envolvidos diretamente na coleta de dados do Projeto BPC no HC/UFMG. Agradecemos tamb&#233;m, pelo constante apoio, &#224; coordena&#231;&#227;o do Hospital do Cora&#231;&#227;o de S&#227;o Paulo - HCor, particularmente ao coordenador do Programa BPC F&#225;bio Papa Taniguchi e sua equipe, composta por Camila Pereira Pinto Toth, Erica Deji Moura Morosov Sabrina Bernardez-Pereira e Suzana Alves Silva.</p>
    </ack>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. GBD 2017 Causes of Death Collaborators. Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-88. doi: 10.1016/S0140-6736(18)32203-7.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>GBD 2017 Causes of Death Collaborators</collab>
          </person-group>
          <article-title>Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980-2017: A Systematic Analysis for the Global Burden of Disease Study 2017</article-title>
          <source> Lancet </source>
          <year>2018</year>
          <volume>392</volume>
          <issue>10159</issue>
          <fpage>1736</fpage>
          <lpage>1788</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32203-7</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Oliveira GMM, Brant LCC, Polanczyk CA, Malta DC, Biolo A, Nascimento BR, et al. Cardiovascular Statistics - Brazil 2021. Arq Bras Cardiol. 2022;118(1):115-373. doi: 10.36660/abc.20211012.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>GMM</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LCC</given-names>
            </name>
            <name>
              <surname>Polanczyk</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Malta</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Biolo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Cardiovascular Statistics - Brazil 2021</article-title>
          <source> Arq Bras Cardiol </source>
          <year>2022</year>
          <volume>118</volume>
          <issue>1</issue>
          <fpage>115</fpage>
          <lpage>373</lpage>
          <issue-id pub-id-type="doi">10.36660/abc.20211012.</issue-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Sociedade Brasileira de Cardiologia &#8211; Diretrizes [Internet]. S&#227;o Paulo: Sociedade Brasileira de Cardiologia; 2022 [cited 2022 Apr 11]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.portal.cardiol.br/diretrizes">https://www.portal.cardiol.br/diretrizes</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Sociedade Brasileira de Cardiologia</collab>
          </person-group>
          <source> Diretrizes </source>
          <comment>Internet</comment>
          <publisher-loc>S&#227;o Paulo</publisher-loc>
          <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
          <year>2022</year>
          <date-in-citation content-type="cited-date">cited 2022 Apr 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://www.portal.cardiol.br/diretrizes">https://www.portal.cardiol.br/diretrizes</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. European Society of Cardiology &#8211; Clinical Practice Guidelines [Internet]. Biot: European Society of Cardiology; 2022 [cited 2022 Apr 11]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines">https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>European Society of Cardiology</collab>
            <collab>Clinical Practice Guidelines</collab>
          </person-group>
          <comment>Internet</comment>
          <source> Biot: European Society of Cardiology </source>
          <year>2022</year>
          <date-in-citation content-type="cited-date">cited 2022 Apr 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines">https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. American Heart Association &#8211; Guidelines and Statements [Internet]. Dallas: American Heart Association; 2022 [cited 2022 Apr 11]. Available from: <ext-link ext-link-type="uri" xlink:href="https://professional.heart.org/en/guidelines-and-statements">https://professional.heart.org/en/guidelines-and-statements</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>American Heart Association</collab>
            <collab>Guidelines and Statements</collab>
          </person-group>
          <comment>Internet</comment>
          <publisher-loc>Dallas</publisher-loc>
          <publisher-name>American Heart Association</publisher-name>
          <year>2022</year>
          <date-in-citation content-type="cited-date">cited 2022 Apr 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://professional.heart.org/en/guidelines-and-statements">https://professional.heart.org/en/guidelines-and-statements</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Lugtenberg M, Burgers JS, Besters CF, Han D, Westert GP. Perceived Barriers to Guideline Adherence: A Survey Among General Practitioners. BMC Fam Pract. 2011;12:98. doi: 10.1186/1471-2296-12-98.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lugtenberg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burgers</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Besters</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Westert</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Perceived Barriers to Guideline Adherence: A Survey Among General Practitioners</article-title>
          <source> BMC Fam Pract </source>
          <year>2011</year>
          <volume>12</volume>
          <size units="pages">98</size>
          <issue-id pub-id-type="doi">10.1186/1471-2296-12-98</issue-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Wang R, Neuenschwander FC, Lima A Filho, Moreira CM, Santos ES, Reis HJ, et al. Use of Evidence-Based Interventions in Acute Coronary Syndrome - Subanalysis of the ACCEPT Registry. Arq Bras Cardiol. 2014;102(4):319-26. doi: 10.5935/abc.20140033.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Neuenschwander</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>A</given-names>
              <suffix>Filho</suffix>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>HJ</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Use of Evidence-Based Interventions in Acute Coronary Syndrome - Subanalysis of the ACCEPT Registry</article-title>
          <source> Arq Bras Cardiol </source>
          <year>2014</year>
          <volume>102</volume>
          <issue>4</issue>
          <fpage>319</fpage>
          <lpage>326</lpage>
          <issue-id pub-id-type="doi">10.5935/abc.20140033</issue-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Franken M, Giugliano RP, Goodman SG, Baracioli LM, Godoy LC, Furtado RHM, et al. Performance of Acute Coronary Syndrome Approaches in Brazil: A Report from the BRACE (Brazilian Registry In Acute Coronary Syndromes). Eur Heart J Qual Care Clin Outcomes. 2020;6(4):284-92. doi: 10.1093/ehjqcco/qcz045.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franken</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giugliano</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Baracioli</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Godoy</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Furtado</surname>
              <given-names>RHM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Performance of Acute Coronary Syndrome Approaches in Brazil: A Report from the BRACE (Brazilian Registry In Acute Coronary Syndromes)</article-title>
          <source> Eur Heart J Qual Care Clin Outcomes </source>
          <year>2020</year>
          <volume>6</volume>
          <issue>4</issue>
          <fpage>284</fpage>
          <lpage>292</lpage>
          <issue-id pub-id-type="doi">10.1093/ehjqcco/qcz045</issue-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Albuquerque DC, Souza JD Neto, Bacal F, Rohde LE, Bernardez-Pereira S, Berwanger O, et al. I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes. Arq Bras Cardiol. 2015;104(6):433-42. doi: 10.5935/abc.20150031.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albuquerque</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>JD</given-names>
              <suffix>Neto</suffix>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Bernardez-Pereira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berwanger</surname>
              <given-names>O</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes</article-title>
          <source> Arq Bras Cardiol </source>
          <year>2015</year>
          <volume>104</volume>
          <issue>6</issue>
          <fpage>433</fpage>
          <lpage>442</lpage>
          <issue-id pub-id-type="doi">10.5935/abc.20150031</issue-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10. American Heart Association &#8211; Get with the Guidelines [Internet]. Dallas: American Heart Association; 2022 [cited 2022 Apr 11]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.heart.org/en/professional/quality-improvement">http://www.heart.org/en/professional/quality-improvement</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>American Heart Association</collab>
            <collab>Get with the Guidelines</collab>
          </person-group>
          <comment>Internet</comment>
          <source> Dallas: American Heart Association </source>
          <year>2022</year>
          <date-in-citation content-type="cited-date">cited 2022 Apr 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="http://www.heart.org/en/professional/quality-improvement">http://www.heart.org/en/professional/quality-improvement</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation>11. Taniguchi FP, Bernardez-Pereira S, Silva SA, Ribeiro ALP, Morgan L, Curtis AB, et al. Implementation of a Best Practice in Cardiology (BPC) Program Adapted from Get with the Guidelines&#174;in Brazilian Public Hospitals: Study Design and Rationale. Arq Bras Cardiol. 2020;115(1):92-99. doi: 10.36660/abc.20190393.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taniguchi</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Bernardez-Pereira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>ALP</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>AB</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Implementation of a Best Practice in Cardiology (BPC) Program Adapted from Get with the Guidelines&#174;in Brazilian Public Hospitals: Study Design and Rationale</article-title>
          <source> Arq Bras Cardiol </source>
          <year>2020</year>
          <volume>115</volume>
          <issue>1</issue>
          <fpage>92</fpage>
          <lpage>99</lpage>
          <issue-id pub-id-type="doi">10.36660/abc.20190393</issue-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation>12. Thomas K, Miller A, Poe G. Abstract 252: The Association of Award Recognition from Get with the Guidelines-Resuscitation with Improved Survival Rates in In-Hospital Cardiac Arrest Events. Circ: Cardiovasc Qual Outcomes. 2016;9(suppl 2). doi: 10.1161/circoutcomes.9.suppl_2.252.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Poe</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Abstract 252: The Association of Award Recognition from Get with the Guidelines-Resuscitation with Improved Survival Rates in In-Hospital Cardiac Arrest Events</article-title>
          <source> Circ: Cardiovasc Qual Outcomes </source>
          <year>2016</year>
          <volume>9</volume>
          <supplement>suppl 2</supplement>
          <issue-id pub-id-type="doi">10.1161/circoutcomes.9.suppl_2.252</issue-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation>13. Marcolino MS, Brant LC, Araujo JG, Nascimento BR, Castro LR, Martins P, et al. Implementation of the Myocardial Infarction System of Care in City of Belo Horizonte, Brazil. Arq Bras Cardiol. 2013;100(4):307-14. doi: 10.5935/abc.20130054.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcolino</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Araujo</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>P</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Implementation of the Myocardial Infarction System of Care in City of Belo Horizonte, Brazil</article-title>
          <source> Arq Bras Cardiol </source>
          <year>2013</year>
          <volume>100</volume>
          <issue>4</issue>
          <fpage>307</fpage>
          <lpage>314</lpage>
          <issue-id pub-id-type="doi">10.5935/abc.20130054</issue-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation>14. Lana MLL, Beaton AZ, Brant LCC, Bozzi ICRS, Magalh&#227;es O, Castro LRA, et al. Factors Associated with Compliance to AHA/ACC Performance Measures in a Myocardial Infarction System of Care in Brazil. Int J Qual Health Care. 2017;29(4):499-506. doi: 10.1093/intqhc/mzx059.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lana</surname>
              <given-names>MLL</given-names>
            </name>
            <name>
              <surname>Beaton</surname>
              <given-names>AZ</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LCC</given-names>
            </name>
            <name>
              <surname>Bozzi</surname>
              <given-names>ICRS</given-names>
            </name>
            <name>
              <surname>Magalh&#227;es</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>LRA</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Factors Associated with Compliance to AHA/ACC Performance Measures in a Myocardial Infarction System of Care in Brazil</article-title>
          <source> Int J Qual Health Care </source>
          <year>2017</year>
          <volume>29</volume>
          <issue>4</issue>
          <fpage>499</fpage>
          <lpage>506</lpage>
          <issue-id pub-id-type="doi">10.1093/intqhc/mzx059</issue-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation>15. Brasil. Contralodoria-Geral da Uni&#227;o. Portal da Transpar&#234;ncia do Governo Federal [Internet]. Bras&#237;lia: Controladoria-Geral da Uni&#227;o; 2022 [cited 2022 Apr 11]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.portaltransparencia.gov.br/funcoes/10-saude?ano=2019">https://www.portaltransparencia.gov.br/funcoes/10-saude?ano=2019</ext-link> .</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Brasil</collab>
            <collab>Contralodoria-Geral da Uni&#227;o</collab>
          </person-group>
          <source> Portal da Transpar&#234;ncia do Governo Federal </source>
          <comment>Internet</comment>
          <publisher-loc>Bras&#237;lia</publisher-loc>
          <publisher-name>Controladoria-Geral da Uni&#227;o</publisher-name>
          <year>2022</year>
          <date-in-citation content-type="cited-date">cited 2022 Apr 11</date-in-citation>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://www.portaltransparencia.gov.br/funcoes/10-saude?ano=2019">https://www.portaltransparencia.gov.br/funcoes/10-saude?ano=2019</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation>16. Ribeiro ALP, Duncan BB, Brant LCC, Lotufo PA, Mill JG, Barreto SM. Cardiovascular Health in Brazil: Trends and Perspectives. Circulation. 2016;133(4):422-33. doi: 10.1161/CIRCULATIONAHA.114.008727.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ribeiro</surname>
              <given-names>ALP</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LCC</given-names>
            </name>
            <name>
              <surname>Lotufo</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Mill</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular Health in Brazil: Trends and Perspectives</article-title>
          <source> Circulation </source>
          <year>2016</year>
          <volume>133</volume>
          <issue>4</issue>
          <fpage>422</fpage>
          <lpage>433</lpage>
          <issue-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.008727</issue-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation>17. Passaglia LG, Brant LCC, Nascimento BR, Ribeiro ALP. Impact of Text Messages in a Middle-Income Country to Promote Secondary Prevention After Acute Coronary Syndrome (IMPACS): A Randomized Trial. Medicine (Baltimore). 2019;98(22):e15681. doi: 10.1097/MD.0000000000015681.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Passaglia</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LCC</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>ALP</given-names>
            </name>
          </person-group>
          <article-title>Impact of Text Messages in a Middle-Income Country to Promote Secondary Prevention After Acute Coronary Syndrome (IMPACS): A Randomized Trial</article-title>
          <source> Medicine (Baltimore) </source>
          <year>2019</year>
          <volume>98</volume>
          <issue>22</issue>
          <elocation-id>e15681</elocation-id>
          <issue-id pub-id-type="doi">10.1097/MD.0000000000015681</issue-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation>18. Passaglia LG, Brant LCC, Silva JLP, Nascimento BR, Ribeiro ALP. Text Messages to Promote Secondary Prevention after Acute Coronary Syndrome (IMPACS trial). Int J Cardiovasc Sci. 2021;35(2):202-13. doi:10.36660/ijcs.20200378.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Passaglia</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Brant</surname>
              <given-names>LCC</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>JLP</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>ALP</given-names>
            </name>
          </person-group>
          <article-title>Text Messages to Promote Secondary Prevention after Acute Coronary Syndrome (IMPACS trial)</article-title>
          <source> Int J Cardiovasc Sci </source>
          <year>2021</year>
          <volume>35</volume>
          <issue>2</issue>
          <fpage>202</fpage>
          <lpage>13</lpage>
          <issue-id pub-id-type="doi">10.36660/ijcs.20200378</issue-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation>19. Lewis WR, Ellrodt AG, Peterson E, Hernandez AF, LaBresh KA, Cannon CP, et al. Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly: Findings from the Get with the Guidelines Quality-Improvement Program. Circ Cardiovasc Qual Outcomes. 2009;2(6):633-41. doi: 10.1161/CIRCOUTCOMES.108.824763.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewis</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Ellrodt</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hernandez</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>LaBresh</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Cannon</surname>
              <given-names>CP</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly: Findings from the Get with the Guidelines Quality-Improvement Program</article-title>
          <source> Circ Cardiovasc Qual Outcomes </source>
          <year>2009</year>
          <volume>2</volume>
          <issue>6</issue>
          <fpage>633</fpage>
          <lpage>641</lpage>
          <issue-id pub-id-type="doi">10.1161/CIRCOUTCOMES.108.824763</issue-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation>20. Masoudi FA, Ponirakis A, de Lemos JA, Jollis JG, Kremers M, Messenger JC, et al. Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries. J Am Coll Cardiol. 2017;69(11):1427-1450. doi: 10.1016/j.jacc.2016.12.005.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masoudi</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Ponirakis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lemos</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Jollis</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Kremers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Messenger</surname>
              <given-names>JC</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries</article-title>
          <source> J Am Coll Cardiol </source>
          <year>2017</year>
          <volume>69</volume>
          <issue>11</issue>
          <fpage>1427</fpage>
          <lpage>1450</lpage>
          <issue-id pub-id-type="doi">10.1016/j.jacc.2016.12.005</issue-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <p>Vincula&#231;&#227;o acad&#234;mica</p>
        <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
      </fn>
    </fn-group>
    <fn-group>
      <fn fn-type="financial-disclosure" id="fn7">
        <p>Fontes de financiamento: O presente estudo foi financiado pelo PROADI-SUS e American Heart Association. Dr Ribeiro &#233; financiando em parte pelo CNPq (310790/2021-2 e 465518/2014-1) e pela FAPEMIG (PPM-00428-17 e RED-00081-16).</p>
      </fn>
    </fn-group>
    <fn-group>
      <fn fn-type="other">
        <p>
          <bold>Errata</bold>
        </p>
        <p>Arq Bras Cardiol. 2023; 120(2):e20220247</p>
        <p>No Artigo Original &#8220;Consumo de Oxig&#234;nio e Aptid&#227;o Cardiorrespirat&#243;ria | Diferen&#231;a entre Idade Cronol&#243;gica e Biol&#243;gica Estat&#237;sticas Cardiovasculares do Programa Boas Pr&#225;ticas em Cardiologia &#8211; Dados de um Hospital P&#250;blico Terci&#225;rio Brasileiro&#8221;, com n&#250;mero de DOI: https://doi.org/10.36660/abc.20220247, publicado no peri&#243;dico Arquivos Brasileiros de Cardiologia, Arq Bras Cardiol. 2023; 120(2)e20220247, na p&#225;gina 1, corrigir o nome da autora Carolina Teixeira Cunha &#201;rika para: Carolina Teixeira Cunha.</p>
        <p>Na p&#225;gina 11 corrigir a refer&#234;ncia 18 para: Passaglia LG, Brant LCC, Silva JLP, Nascimento BR, Ribeiro ALP. Text Messages to Promote Secondary Prevention after Acute Coronary Syndrome (IMPACS trial). Int J Cardiovasc Sci. 2021;35(2):202-13. doi:10.36660/ijcs.20200378.</p>
      </fn>
    </fn-group>
    <app-group>
      <app id="app01">
        <title>* Material suplementar</title>
        <p>Para informa&#231;&#227;o adicional do Material Suplementar 1, por favor, <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-1.pdf">clique aqui</ext-link> .</p>
        <p>Para informa&#231;&#227;o adicional do Material Suplementar 2, por favor, <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-2.pdf">clique aqui</ext-link> .</p>
      </app>
    </app-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cardiovascular Statistics from the Good Practices in Cardiology Program &#8211; Data from a Brazilian Tertiary Public Hospital</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-8260-9212</contrib-id>
          <name>
            <surname>Passaglia</surname>
            <given-names>Luiz Guilherme</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis and Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9601-7189</contrib-id>
          <name>
            <surname>Cerqueira</surname>
            <given-names>Marina L&#237;rio Resende</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis and Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pires</surname>
            <given-names>Mariana Martins</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis and Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chagas</surname>
            <given-names>Lucas Vieira</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis and Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cunha</surname>
            <given-names>Carolina Teixeira</given-names>
          </name>
          <role>Acquisition of data</role>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodrigues</surname>
            <given-names>Erika Nunes de Oliveira</given-names>
          </name>
          <role>Acquisition of data</role>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Diniz</surname>
            <given-names>Fl&#225;via Mariana Mendes</given-names>
          </name>
          <role>Acquisition of data</role>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Darkiane Fernandes</given-names>
          </name>
          <role>Acquisition of data</role>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nogueira</surname>
            <given-names>Monique Rocha</given-names>
          </name>
          <role>Acquisition of data</role>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Braga</surname>
            <given-names>Gisia Teodoro</given-names>
          </name>
          <role>Acquisition of data</role>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taniguchi</surname>
            <given-names>F&#225;bio P.</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Obtaining financing</role>
          <xref ref-type="aff" rid="aff4001">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Antonio Luiz Pinho</given-names>
          </name>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff5001">
            <sup>5</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Minas Gerais &#8211; Servi&#231;o de Cardiologia e Cirurgia Card&#237;aca do Hospital das Cl&#237;nicas, Belo Horizonte, MG &#8211; Brasil</institution>
      </aff>
      <aff id="aff2001">
        <label>2</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Minas Gerais &#8211; Faculdade de Medicina, Belo Horizonte, MG &#8211; Brasil</institution>
      </aff>
      <aff id="aff3001">
        <label>3</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Minas Gerais &#8211; Equipe de Enfermagem do Hospital das Cl&#237;nicas, Belo Horizonte, MG &#8211; Brasil</institution>
      </aff>
      <aff id="aff4001">
        <label>4</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital do Cora&#231;&#227;o (Hcor), S&#227;o Paulo, SP &#8211; Brasil</institution>
      </aff>
      <aff id="aff5001">
        <label>5</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Minas Gerais &#8211; Departamento de Cl&#237;nica M&#233;dica da UFMG e Centro de Teless&#225;ude do Hospital das Cl&#237;nicas,Belo Horizonte, MG &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001">Mailing Address: Luiz Guilherme Passaglia &#8226; Universidade Federal de Minas Gerais - Servi&#231;o de Cardiologia e CCV do HC-UFMG - Avenida Alfredo Balena, 110. Postal Code 30130-100, Santa Efig&#234;nia, Belo Horizonte, MG - Brazil E-mail: lg.passaglia@uol.com.br</corresp>
        <fn fn-type="conflict">
          <p>Potential Conflict of Interest</p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <abstract>
        <title>Abstract</title>
        <sec>
          <title>Background</title>
          <p>The Good Practices in Cardiology Program is an initiative created by the Brazilian Society of Cardiology (SBC) to improve the quality of care of cardiovascular disease patients in Brazilian public hospitals.</p>
        </sec>
        <sec>
          <title>Objectives</title>
          <p>To characterize patients admitted to a tertiary public hospital with diagnosis of acute coronary syndrome (ACS) or heart failure (HF) and to evaluate performance indicators in both ACS and HF arms, with a pre-established target of 85% adherence to the SBC recommendations.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>This was a descriptive cross-sectional study through data collection of patients hospitalized between May 2016 and September 2019.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>A total of 1,036 patients were included, 273 in the HF arm and 763 in the ACS arm. Mean age was 59.8 &#177; 12.0 years in the ACS and 57.0 &#177; 14.1 years in the HF, with a predominance of male patients in both groups. More than half of patients had some primary education and more than 90% reported a monthly income of less than five minimum wages. In ACS, the diagnosis of ACS with ST segment elevation was predominant (66.3%), and 2.9% of patients died. In HF, the most common etiology was Chagas disease (25.8%), and 17.9% died. Analysis of the performance indicators revealed an adherence rate higher than 85% to nine of the 12 indicators.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Quality programs are essential for improvement of quality of care. Performance indicators pointed to a good adherence to the SBC guidelines, mainly in the ACS arm.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Cardiovascular Diseases</kwd>
        <kwd>Acute Coronary Syndrome</kwd>
        <kwd>Heart Failure</kwd>
        <kwd>Quality Improvement</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>Cardiovascular diseases (CVD) are the main cause of death in the world and one of the five leading causes of years of healthy life lost.<sup><xref ref-type="bibr" rid="B1">1</xref></sup>In Brazil, acute coronary syndrome (ACS) and heart failure (HF) are the main causes of death and hospitalization, respectively.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
        <p>National and international organizations have developed and spread recommendations by clinical guidelines to help healthcare professionals in the management of CVD.<sup><xref ref-type="bibr" rid="B3">3</xref> - <xref ref-type="bibr" rid="B5">5</xref> </sup>Despite the vast number of publications of proven effective therapies, the adherence to guidelines&#8217; recommendations is still lower than ideal,<sup><xref ref-type="bibr" rid="B6">6</xref></sup>particularly in Brazilian hospitals, as reported in the ACCEPT,<sup><xref ref-type="bibr" rid="B7">7</xref></sup>BRACE,<sup><xref ref-type="bibr" rid="B8">8</xref></sup>and BREATHE<sup><xref ref-type="bibr" rid="B9">9</xref></sup>registries.</p>
        <p>In this context, programs for healthcare quality improvement have been developed trying to assure an adequate care for CVD patients. In the United States, the Get With The Guidelines (GWTG) initiative was created by the American Heart Association (AHA) and the American Stroke Association to improve the care of these patients.<sup><xref ref-type="bibr" rid="B10">10</xref></sup>In Brazil, the Brazilian Society of Cardiology (SBC) and the Ministry of Health, together with the AHA and with the collaboration of Hcor (Hospital do Cora&#231;&#227;o) in Sao Paulo, created the Good Practices in Cardiology program (GPC program). This program is aimed at evaluating the rates of adherence to the recommendations of the SBC guidelines and results of the implementation of a quality program regarding clinical outcomes of hospitalized patients with CVD.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
        <p>Then, the present study aimed to characterize hospitalization data of patients with ACS and HF, participants of the GPC program, in a Brazilian public tertiary hospital, and to evaluate the rates of adherence to evidence-based therapies established by the SBC and defined as performance indicators.</p>
      </sec>
      <sec sec-type="methods">
        <title>Methods</title>
        <p>This was a descriptive cross-sectional study of analysis of data of patients hospitalized in the General Hospital of the Federal University of Minas Gerais (UFMG) between May 2016 and September 2019 with the primary diagnosis of HF or ACS. Design and basis of the program have been previously published in detail,<sup><xref ref-type="bibr" rid="B11">11</xref></sup>and the arms conducted in this hospital were approved by the ethics committee of the UFMG (approval number 1.487.029, April 11, 2016).</p>
        <sec>
          <title>Population</title>
          <p>Patients aged 18 years or older, admitted with the primary diagnosis of ACS (ICD-10 I20.0 - I21.9 and I22.0 - I22.9) or HF (ICD-10 codes I50.0; I50.1 or I50.9), regardless of previous history of these conditions, were included in the study. Exclusion criteria were:</p>
          <p>(A) Patients with ACS secondary to elective myocardial revascularization (elective percutaneous coronary intervention or myocardial revascularization surgery) or to major, non-cardiac surgeries during hospitalization;</p>
          <p>(B) Patients with a history of HF, admitted to the emergency department with a confirmed diagnosis of dyspnea for other causes. Patients admitted for HF, patients with planned transfer to another institution and those with planned hospitalization for less than 24 hours were also excluded.</p>
        </sec>
        <sec>
          <title>Data collection</title>
          <p>After screening for eligibility criteria, patients were invited to participate in the GPC program during their hospitalization, and all those willing to participate signed an informed consent form. Data were collected from the medical records and through a structured in-person interview conducted by trained investigators, using specific forms developed to the GPC program.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
        </sec>
        <sec>
          <title>Outcomes</title>
          <p>The primary outcome of the GPC program was adherence rates, by the care staff, to the performance indicators, which are quality metrics determined by class I recommendations of the SBC and AHA guidelines, described in detail in the article by Thomas et al.<sup><xref ref-type="bibr" rid="B11">11</xref></sup>and in the GPC website (http://www.cardiol.br/boaspraticasclinicas/).</p>
          <p>The performance indicators in the ACS arm were ( <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-1.pdf">Supplement 1</ext-link> ):</p>
          <list list-type="order">
            <list-item>
              <p>Early aspirin use;</p>
            </list-item>
            <list-item>
              <p>Adequate reperfusion therapy (door-to-needle time and door-to-balloon time);</p>
            </list-item>
            <list-item>
              <p>Aspirin at discharge;</p>
            </list-item>
            <list-item>
              <p>Angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB) at discharge of patients with left ventricular ejection fraction (LVEF) &lt; 45%;</p>
            </list-item>
            <list-item>
              <p>Beta-blocker at discharge;</p>
            </list-item>
            <list-item>
              <p>Statins at discharge;</p>
            </list-item>
            <list-item>
              <p>Blood pressure control at discharge;</p>
            </list-item>
            <list-item>
              <p>Tobacco cessation counseling for active smokers at discharge.</p>
            </list-item>
          </list>
          <p>The performance indicators in the HF arm were ( <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-1.pdf">Supplement 1</ext-link> ):</p>
          <list list-type="order">
            <list-item>
              <p>Left ventricular function assessment by echocardiogram;</p>
            </list-item>
            <list-item>
              <p>ACEI or ARB at discharge;</p>
            </list-item>
            <list-item>
              <p>Beta-blocker at discharge;</p>
            </list-item>
            <list-item>
              <p>Spironolactone at discharge;</p>
            </list-item>
            <list-item>
              <p>Post-discharge visit (outpatient follow-up scheduled at discharge)</p>
            </list-item>
          </list>
          <p>For the GPC program, a minimum of 85% adherence rate to the performance indicators above described was established, based on previous results of the GWTG program.<sup><xref ref-type="bibr" rid="B12">12</xref></sup></p>
        </sec>
        <sec>
          <title>Statistical analysis</title>
          <p>Since this was a descriptive observational study of a convenience sample, the sample size was not calculated. Continuous variables were described as mean and standard deviation or as median and interquartile range (Q1, Q3), according to results of the Shapiro-Wilk normality test. The level of significance was set at 5%. Categorical variables were expressed as proportions. Only valid data were included in the analyses. Thus, patients with missing data and patients with contraindications to the medications that composed the performance indicators, recorded in the medical records. Data were analyzed using the SPSS software version 20.1 (IBM Corp, Armonk, NY, US).</p>
        </sec>
      </sec>
      <sec sec-type="results">
        <title>Results</title>
        <p>A total of 1036 patients were included, 763 with diagnosis of ACS (ACS arm) and 273 patients with diagnosis of HF (HF arm). Mean age of participants was 59.8 &#177; 12.0 years in the ACS arm and 57.0 &#177; 14.1 years in the HF arm, with predominance of male patients in both.</p>
        <p>Main comorbidities of the patients were hypertension, diabetes, and dyslipidemia. In the HF arm, there was also a high proportion of patients with hypothyroidism and other underlying diseases. A considerable number of patients reported current or past smoking, especially in the ACS arm ( <xref ref-type="table" rid="t1001">Table 1</xref> ).</p>
        <p>
          <table-wrap id="t1001">
            <label>Table 1</label>
            <caption>
              <title>&#8211; Characteristics of the sample at hospital admission (general data and medical history)</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" colspan="2" scope="col">Variable</th>
                  <th scope="col">Acute coronary syndrome (763)</th>
                  <th scope="col">Heart failure (273)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" colspan="2">Age, m &#177; sd*</td>
                  <td align="center">59.8 &#177; 12.0</td>
                  <td align="center">57.0 &#177; 14.1</td>
                </tr>
                <tr>
                  <td align="left" colspan="2">Female sex</td>
                  <td align="center">225/763 (29.5%)</td>
                  <td align="center">119/273 (43.6%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="7">Comorbidities</td>
                  <td>Systemic arterial hypertension</td>
                  <td align="center">497/633 (78.5%)</td>
                  <td align="center">108/260 (41.5%)</td>
                </tr>
                <tr>
                  <td align="center">Diabetes Mellitus</td>
                  <td align="center">220/633 (34.8%)</td>
                  <td align="center">69/260 (26.5%)</td>
                </tr>
                <tr>
                  <td align="center">Dyslipidemia</td>
                  <td align="center">171/633 (27.0%)</td>
                  <td align="center">38/260 (14.6%)</td>
                </tr>
                <tr>
                  <td align="center">Stroke or transient ischemic attack</td>
                  <td align="center">49/633 (7.7%)</td>
                  <td align="center">18/260 (12.3%)</td>
                </tr>
                <tr>
                  <td align="center">Peripheral arterial disease</td>
                  <td align="center">38/633 (6.0%)</td>
                  <td align="center">17/260 (6.5%)</td>
                </tr>
                <tr>
                  <td align="center">Hypothyroidism</td>
                  <td align="center">35/633 (5.5%)</td>
                  <td align="center">41/260 (15.8%)</td>
                </tr>
                <tr>
                  <td align="center">Chronic pulmonary obstructive disease/Asthma</td>
                  <td align="center">47/633 (7.4%)</td>
                  <td align="center">29/260 (11.2%)</td>
                </tr>
                <tr>
                  <td rowspan="6">Previous heart disease</td>
                  <td align="center">Coronary disease</td>
                  <td align="center">162/633 (25.6%)</td>
                  <td align="center">29/260 (11.2%)</td>
                </tr>
                <tr>
                  <td align="center">Acute myocardial infarction</td>
                  <td align="center">119/633 (18.8%)</td>
                  <td align="center">44/260 (16.9%)</td>
                </tr>
                <tr>
                  <td align="center">Heart failure</td>
                  <td align="center">30/633 (4.7%)</td>
                  <td align="center">236/260 (90.8%)</td>
                </tr>
                <tr>
                  <td align="center">Atrial fibrillation or atrial flutter</td>
                  <td align="center">21/633 (3.3%)</td>
                  <td align="center">99/260 (38.1%)</td>
                </tr>
                <tr>
                  <td align="center">Heart valve disease</td>
                  <td align="center">8/633 (1.3%)</td>
                  <td align="center">39/264 (15.2%)</td>
                </tr>
                <tr>
                  <td align="center">Chagas disease</td>
                  <td align="center">6/633 (0.8%)</td>
                  <td align="center">66/264 (25.8%)</td>
                </tr>
                <tr>
                  <td rowspan="6">Previous cardiac procedures</td>
                  <td align="center">Coronary angioplasty</td>
                  <td align="center">98/763 (12.8%)</td>
                  <td align="center">31/273 (11.4%)</td>
                </tr>
                <tr>
                  <td align="center">Myocardial revascularization surgery</td>
                  <td align="center">39/763 (5.1%)</td>
                  <td align="center">8/273 (2.9%)</td>
                </tr>
                <tr>
                  <td align="center">Pacemaker</td>
                  <td align="center">6/763 (0.8%)</td>
                  <td align="center">43/273 (15.8%)</td>
                </tr>
                <tr>
                  <td align="center">Cardiac resynchronization</td>
                  <td align="center">2/763 (0.3%)</td>
                  <td align="center">4/273 (1.5%)</td>
                </tr>
                <tr>
                  <td align="center">Cardioverter-defibrillator</td>
                  <td align="center">5/763 (0.7%)</td>
                  <td align="center">39/273 (14.3%)</td>
                </tr>
                <tr>
                  <td align="center">Cardiac transplantation</td>
                  <td align="center">-</td>
                  <td align="center">9/273 (6.3%)</td>
                </tr>
                <tr>
                  <td rowspan="4">Smoking</td>
                  <td align="center">Current and previous (total)</td>
                  <td align="center">509/761 (66.8%)</td>
                  <td align="center">139/266 (55.3%)</td>
                </tr>
                <tr>
                  <td align="center">Current</td>
                  <td align="center">253/761 (33.2%)</td>
                  <td align="center">21/266 (7.9%)</td>
                </tr>
                <tr>
                  <td align="center">Previous</td>
                  <td align="center">256/761 (33.6%)</td>
                  <td align="center">118/266 (44.4%)</td>
                </tr>
                <tr>
                  <td align="center">No</td>
                  <td align="center">252/761 (33.1%)</td>
                  <td align="center">127/266 (47.7%)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN1001">
                <p>
                  <italic>* Variable as mean &#177; standard deviation (m&#177;sd)</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>More than half of patients included in the study have not finished elementary school and more than 90% reported a monthly income lower than five minimum wages ( <xref ref-type="table" rid="t2001">Table 2</xref> ).</p>
        <p>
          <table-wrap id="t2001">
            <label>Table 2</label>
            <caption>
              <title>&#8211; Characteristics of socioeconomic variables</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left">Variable</th>
                  <th align="left" style="font-weight:normal"> </th>
                  <th>Acute coronary syndrome (763)</th>
                  <th>Heart failure (273)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="7">Educational attainment</td>
                  <td align="center">Illiterate</td>
                  <td align="center">72/761 (9.5%)</td>
                  <td align="center">29/268 (10.8%)</td>
                </tr>
                <tr>
                  <td align="center">Some primary education</td>
                  <td align="center">372/761 (48.9%)</td>
                  <td align="center">127/268 (47.4%)</td>
                </tr>
                <tr>
                  <td align="center">Complete primary education</td>
                  <td align="center">91/761 (12.0%)</td>
                  <td align="center">38/268 (14.2%)</td>
                </tr>
                <tr>
                  <td align="center">Some secondary education</td>
                  <td align="center">67/761 (8.8%)</td>
                  <td align="center">12/268 (4.5%)</td>
                </tr>
                <tr>
                  <td align="center">Complete secondary education</td>
                  <td align="center">85/761 (11.2%)</td>
                  <td align="center">52/268 (19.4%)</td>
                </tr>
                <tr>
                  <td align="center">Some higher education</td>
                  <td align="center">34/761 (4.5%)</td>
                  <td align="center">5/268 (1.9%)</td>
                </tr>
                <tr>
                  <td align="center">Complete higher education</td>
                  <td align="center">40/761 (5.3%)</td>
                  <td align="center">5/268 (1.9%)</td>
                </tr>
                <tr>
                  <td rowspan="5">Family income</td>
                  <td align="center">&#8804; 1 minimum wage</td>
                  <td align="center">192/761 (25.2%)</td>
                  <td align="center">76/268 (28.4%)</td>
                </tr>
                <tr>
                  <td align="center">&gt; 1 - &#8804; 2 minimum wages</td>
                  <td align="center">276/761 (36.3%)</td>
                  <td align="center">131/268 (48.9%)</td>
                </tr>
                <tr>
                  <td align="center">&gt; 2 - &#8804; 5 minimum wages</td>
                  <td align="center">226/761 (29.7%)</td>
                  <td align="center">46/268 (17.2%)</td>
                </tr>
                <tr>
                  <td align="center">&gt; 5 - &#8804; 10 minimum wages</td>
                  <td align="center">47/761 (6.2%)</td>
                  <td align="center">12/268 (4.5%)</td>
                </tr>
                <tr>
                  <td align="center">&gt; 10 minimum wages</td>
                  <td align="center">20/761 (2.6%)</td>
                  <td align="center">3/268 (1.1%)</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </p>
        <p>In the ACS arm ( <xref ref-type="table" rid="t3001">Table 3</xref> ), most patients were Killip-Kimball class I-II (81.6%) and more than one third (37.4%) had recurrent chest pain in the first 24 hours of admission. Acute myocardial infarction (AMI) with ST-segment elevation was the predominant diagnosis (66.3%); 42.9% of these patients were thrombolysed, 33.8% underwent primary angioplasty and 23.3% did not undergo any reperfusion therapy.</p>
        <p>
          <table-wrap id="t3001">
            <label>Table 3</label>
            <caption>
              <title>&#8211; Characteristics of patients with acute coronary syndrome at hospital admission</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <tbody>
                <tr>
                  <td align="left" rowspan="3">Type of acute coronary syndrome</td>
                  <td align="center" colspan="2">Unstable angina</td>
                  <td align="center">94/758 (12.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">AMI without ST elevation</td>
                  <td align="center">156/758 (20.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">AMI with ST elevation</td>
                  <td align="center">506/758 (66.7%)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="4">Killip-Kimball classification</td>
                  <td align="center" colspan="2">Killip I</td>
                  <td align="center">491/755 (65.0%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Killip II</td>
                  <td align="center">125/755 (16.5%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Killip III</td>
                  <td align="center">55/755 (7.2%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Killip IV</td>
                  <td align="center">58/755 (7.7%)</td>
                </tr>
                <tr>
                  <td align="left" colspan="3">Cardiorespiratory arrest at admission</td>
                  <td align="center">59/759 (7.8%)</td>
                </tr>
                <tr>
                  <td colspan="3">Recurrence of pain in the first 24h</td>
                  <td align="center">220/589 (37.4%)</td>
                </tr>
                <tr>
                  <td rowspan="5">Laboratory tests at admission*</td>
                  <td align="center" colspan="2">Creatinine mg/dL &#8211; mean &#177; SD</td>
                  <td align="center">0.96 &#177; 0.2</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Total cholesterol mg/dL - median (IIQ)</td>
                  <td align="center">168 (140-202)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">LDL-C mg/dL - median (IQR)</td>
                  <td align="center">98 (72-129)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">HDL-C mg/dL - median (IQR)</td>
                  <td align="center">41 (34-49)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Triglycerides. mg/dL - median (IQR)</td>
                  <td align="center">112 (76-170)</td>
                </tr>
                <tr>
                  <td colspan="3">Candidates for reperfusion</td>
                  <td align="center">506/757 (67.1%)</td>
                </tr>
                <tr>
                  <td rowspan="4">Pharmacological reperfusion therapy</td>
                  <td align="center" colspan="2">Thrombolytics</td>
                  <td align="center">217/506 (42.9%)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="3">Type of thrombolytic agent</td>
                  <td align="center">Streptokinase</td>
                  <td align="center">1/217 (0.5%)</td>
                </tr>
                <tr>
                  <td align="center">Alteplase</td>
                  <td align="center">175/217 (80.6%)</td>
                </tr>
                <tr>
                  <td align="center">Not documented</td>
                  <td align="center">41/217 (18.9%)</td>
                </tr>
                <tr>
                  <td rowspan="4">Coronary angiography</td>
                  <td align="center" colspan="2">Diagnostic coronary angiography</td>
                  <td align="center">706/757 (93.3%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">PCI of the culprit artery</td>
                  <td align="center">495/756 (65.5%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Primary PCI</td>
                  <td align="center">171/506 (33.8%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Rescue PCI</td>
                  <td align="center">84/495 (17.0%)</td>
                </tr>
                <tr>
                  <td rowspan="6">Coronary angiography (site of the lesions)</td>
                  <td align="center" colspan="2">No lesions</td>
                  <td align="center">45/547 (8.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">One vessel</td>
                  <td align="center">150/547 (27.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Two vessels</td>
                  <td align="center">145/547 (26.5%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Three vessels</td>
                  <td align="center">207/547 (37.8%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">LCA lesion</td>
                  <td align="center">21/547 (3.8%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Lesion of the proximal DA</td>
                  <td align="center">187/547 (34.2%)</td>
                </tr>
                <tr>
                  <td colspan="3">Left ventricular ejection fraction, % - md (IQR)*</td>
                  <td align="center">54 (43-62)</td>
                </tr>
                <tr>
                  <td colspan="3">Myocardial revascularization surgery</td>
                  <td align="center">43/763 (5.6%)</td>
                </tr>
                <tr>
                  <td colspan="3">Number of days in intensive care &#8211; median (IQR)*</td>
                  <td>4 (3-6)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN2001">
                <p>
                  <italic>HDL: high-density lipoprotein; LDL: low-density lipoprotein; AMI: acute myocardial infarction; PCI: percutaneous coronary intervention; LCA: left coronary artery; DA: descending aorta; SD: standard deviation; IQR: interquartile range. Variables presented as mean &#177; standard deviation (SD) or median and 1<sup><italic>st</italic></sup>and 3rd quartiles.</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>In the HF arm ( <xref ref-type="table" rid="t4001">Table 4</xref> and <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-2.pdf">Supplement 2</ext-link> ), the most common etiologies were Chagas disease (25.8%), idiopathic disease (22.3%), ischemic heart disease (15.2%) and heart valve disease (15.2%). Most patients were NYHA functional class III-IV (76.4%), and most had a &#8220;warm and wet&#8221; hemodynamic profile (60.1%) on admission. Mean LVEF was 35.0% &#177; 9.0% and 50 patients (18.3%) were referred for heart transplantation during the same hospitalization. Dobutamine was used at any time during hospitalization in 53.9% of the patients, either for the &#8220;cold&#8221; profile on admission or for progression to signs of low cardiac output; intravenous furosemide was administered in bolus doses in 90.2% of patients and by continuous infusion using an infusion pump in 25.4%.</p>
        <p>
          <table-wrap id="t4001">
            <label>Table 4</label>
            <caption>
              <title>&#8211; Characteristics of heart failure patients at hospital admission</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <tbody>
                <tr>
                  <td rowspan="8">Etiology of heart failure</td>
                  <td align="center">Chagas disease</td>
                  <td align="center">66/264 (25.8%)</td>
                </tr>
                <tr>
                  <td align="center">idiopathic</td>
                  <td align="center">57/264 (22.3%)</td>
                </tr>
                <tr>
                  <td align="center">Ischemic</td>
                  <td align="center">39/264 (15.2%)</td>
                </tr>
                <tr>
                  <td align="center">Valvular</td>
                  <td align="center">39/264 (15.2%)</td>
                </tr>
                <tr>
                  <td align="center">Hypertrophic</td>
                  <td align="center">8/264 (3.1%)</td>
                </tr>
                <tr>
                  <td align="center">Cardiotoxicity</td>
                  <td align="center">5/264 (2.0%)</td>
                </tr>
                <tr>
                  <td align="center">Hypertensive</td>
                  <td align="center">5/264 (2.0%)</td>
                </tr>
                <tr>
                  <td align="center">Others</td>
                  <td align="center">45/264 (17.0%)</td>
                </tr>
                <tr>
                  <td rowspan="4">Number of hospitalizations in the last six months</td>
                  <td align="center">0</td>
                  <td align="center">44/184 (23.9%)</td>
                </tr>
                <tr>
                  <td align="center">1</td>
                  <td align="center">40/184 (21.7%)</td>
                </tr>
                <tr>
                  <td align="center">2</td>
                  <td align="center">42/184 (22.8%)</td>
                </tr>
                <tr>
                  <td align="center">&gt; 2</td>
                  <td align="center">58/184 (31.5%)</td>
                </tr>
                <tr>
                  <td rowspan="4">New York Heart Association (NYHA) functional class</td>
                  <td align="center">I</td>
                  <td align="center">3/254 (1.2%)</td>
                </tr>
                <tr>
                  <td align="center">II</td>
                  <td align="center">16/254 (5.9%)</td>
                </tr>
                <tr>
                  <td align="center">III</td>
                  <td align="center">70/254 (27.6%)</td>
                </tr>
                <tr>
                  <td align="center">IV</td>
                  <td align="center">124/254 (48.8%)</td>
                </tr>
                <tr>
                  <td rowspan="2">Patient on the waiting list for heart transplantation</td>
                  <td align="center">Yes</td>
                  <td align="center">70/259 (27%)</td>
                </tr>
                <tr>
                  <td align="center">No</td>
                  <td align="center">189/259 (73%)</td>
                </tr>
                <tr>
                  <td rowspan="4">Hemodynamic profile</td>
                  <td align="center">Warm and dry</td>
                  <td align="center">8/253 (3.2%)</td>
                </tr>
                <tr>
                  <td align="center">Warm and wet</td>
                  <td align="center">152/253 (60.1%)</td>
                </tr>
                <tr>
                  <td align="center">Cold and wet</td>
                  <td align="center">62/253 (24.5%)</td>
                </tr>
                <tr>
                  <td align="center">Cold and dry</td>
                  <td align="center">8/253 (3.2%)</td>
                </tr>
                <tr>
                  <td rowspan="7">Cause of decompensation</td>
                  <td align="center">Non-adherence to medication</td>
                  <td align="center">23/273 (8.4%)</td>
                </tr>
                <tr>
                  <td align="center">Non-compliance with dietary and water intake recommendations</td>
                  <td align="center">11/273 (4.0%)</td>
                </tr>
                <tr>
                  <td align="center">Uncontrolled hypertension</td>
                  <td align="center">5/273 (1.8%)</td>
                </tr>
                <tr>
                  <td align="center">Infection</td>
                  <td align="center">42/273 (15.4%)</td>
                </tr>
                <tr>
                  <td align="center">Arrhythmia</td>
                  <td align="center">46/273 (16.8%)</td>
                </tr>
                <tr>
                  <td align="center">Decompensated renal failure</td>
                  <td align="center">11/273 (4.0%)</td>
                </tr>
                <tr>
                  <td align="center">Ischemia or acute coronary syndrome</td>
                  <td align="center">14/273 (5.1%)</td>
                </tr>
                <tr>
                  <td rowspan="2">Echocardiographic data *</td>
                  <td align="center">Left ventricular ejection fraction, % - m&#177;sd</td>
                  <td align="center">35.0 &#177; 9.0</td>
                </tr>
                <tr>
                  <td align="center">Left atrial diameter, millimeter - m&#177;sd</td>
                  <td align="center">49.5 &#177; 9.0</td>
                </tr>
                <tr>
                  <td rowspan="2">Other data of hospitalization</td>
                  <td align="center">Prophylaxis of deep vein thrombosis</td>
                  <td align="center">237/256 (92.6%)</td>
                </tr>
                <tr>
                  <td align="center">Weight recordings (at least 70% of hospitalization period)</td>
                  <td align="center">173/256 (67.8%)</td>
                </tr>
                <tr>
                  <td rowspan="2">Discontinuation of beta-blockers at admission or during hospitalization</td>
                  <td align="center">Yes</td>
                  <td align="center">81/141 (57.4%)</td>
                </tr>
                <tr>
                  <td align="center">No</td>
                  <td align="center">60/141 (42.6%)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN3001">
                <p>
                  <italic>* Complete data available in the system (variable denominator) &#8211; echocardiographic data (217 patients). Variable presented as mean &#177; standard deviation (m&#177;sd)</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p><xref ref-type="table" rid="t5001">Tables 5</xref> and <xref ref-type="table" rid="t6001">6</xref> describe data of in-hospital mortality and hospital discharge. During hospitalization, 2.9% of patients in the ACS arm and 17.9% in HF arm died.</p>
        <p>
          <table-wrap id="t5001">
            <label>Table 5</label>
            <caption>
              <title>&#8211; Characteristics of patients with acute coronary syndrome on discharge</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" colspan="4" scope="col">In-hospital mortality</th>
                  <th scope="col">22/763 (2.9%)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" colspan="2" rowspan="12">Medications on discharge</td>
                  <td align="center" colspan="2">Acetylsalicylic acid</td>
                  <td align="center">700/733 (95.5%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">P2Y2 Inhibitors</td>
                  <td align="center">657/733 (89.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Anticoagulant</td>
                  <td align="center">94/733 (12.8%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="1">BB</td>
                  <td align="center">616/657 (93.7%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="1"> </td>
                  <td align="center">BB contraindicated for 76/733 (10.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="1">ACEI</td>
                  <td align="center">439/596 (73.7%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="1"> </td>
                  <td align="center">ACEI contraindicated for 137/733 (18.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="1">ARB</td>
                  <td align="center">142/635 (22.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="1"> </td>
                  <td align="center">ARB contraindicated for 98/733 (13.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Statin</td>
                  <td align="center">707/733 (96.5%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="2">Spironolactone</td>
                  <td align="center">78/486 (16.0%)</td>
                </tr>
                <tr>
                  <td align="center">Spironolactone was contraindicated for 247/733 (33.7%)</td>
                </tr>
                <tr>
                  <td colspan="2" rowspan="3">Clinical data on discharge*</td>
                  <td align="center" colspan="2">SBP - mmHg, md (IQR)</td>
                  <td align="center">113 (100-130)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">DBP - mmHg, md (IQR)</td>
                  <td align="center">70 (60-80)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">HR. beats per minute &#8211; md (IQR)</td>
                  <td align="center">68 (63-78)</td>
                </tr>
                <tr>
                  <td rowspan="29">Instructions</td>
                  <td align="center" rowspan="4">Smoking cessation<sup>&#8224;</sup></td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">277/340 (81.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">No</td>
                  <td align="center">3/340 (0.9%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Non-applicable</td>
                  <td align="center">393/733 (53.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">60/340 (17.6%)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="3">Lifestyle change</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">670/733 (91.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">No</td>
                  <td align="center">16/733 (2.2%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">46/733 (6.3%)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="4">Weight control</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">546/710 (76.9%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">No</td>
                  <td align="center">24/710 (3.3%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Non-applicable</td>
                  <td align="center">23/733 (3.1%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">140/710 (19.7%)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="3">Physical exercise</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">660/733 (90.0%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">No</td>
                  <td align="center">17/733 (2.3%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">56/733 (7.7%)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="4">Referred for rehabilitation<sup>&#8224;</sup></td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">615/721 (85.2%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">No</td>
                  <td align="center">32/721 (4.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Non-applicable</td>
                  <td align="center">12/733 (1.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">74/721 (10.3%)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="3">Use of prescribed medications</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">677/733 (92.4%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">No</td>
                  <td align="center">9/733 (1.2%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">47/733 (6.4%)</td>
                </tr>
                <tr>
                  <td align="center" rowspan="4">Outpatient follow-up</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">717/733 (97.8%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">No</td>
                  <td align="center">4/733 (0.5%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Non-applicable</td>
                  <td align="center">0/733 (0.0%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">12/733 (1.7%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="4">Anticoagulant therapy<sup>&#8224;</sup></td>
                  <td align="center">Yes</td>
                  <td align="center">85/114 (74.6%)</td>
                </tr>
                <tr>
                  <td align="center">No</td>
                  <td align="center">14/114 (12.3%)</td>
                </tr>
                <tr>
                  <td align="center">Non-applicable</td>
                  <td align="center">619/733 (84.4%)</td>
                </tr>
                <tr>
                  <td align="center">Not documented</td>
                  <td align="center">15/114 (13.1%)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN4001">
                <p>
                  <italic>BB: beta-blocker; ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blocker; HR: heart rate; DBP: diastolic blood pressure; SBP: systolic blood pressure. * Variables as median and 1st and 3rd quartiles [md (IQR)]; &#8224; Calculated based on patients to whom this therapy is indicated.</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>
          <table-wrap id="t6001">
            <label>Table 6</label>
            <caption>
              <title>&#8211; Characteristics of patients with heart failure on discharge</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" colspan="4" scope="col" style="font-weight:normal">In-hospital mortality</th>
                  <th scope="col" style="font-weight:normal">49/273 (17.9%)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" colspan="2" rowspan="15"> </td>
                  <td align="center" colspan="2">Anticoagulant</td>
                  <td align="center">93/206 (45.1%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="2">BB</td>
                  <td align="center">136/145 (93.8%)</td>
                </tr>
                <tr>
                  <td align="center">BB contraindicated for 61/206 (29.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="2">ACEI</td>
                  <td align="center">72/128 (56.2%)</td>
                </tr>
                <tr>
                  <td align="center">ACEI contraindicated for 78/206 (37.9%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="2">ARB</td>
                  <td align="center">48/145 (33.1%)</td>
                </tr>
                <tr>
                  <td align="center">ARB contraindicated for 61/206 (29.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Hydralazine</td>
                  <td align="center">27/206 (13.1%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Nitrate</td>
                  <td align="center">23/206 (11.2%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Antiarrhythmics</td>
                  <td align="center">30/206 (14.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Digoxin</td>
                  <td align="center">26/206 (12.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Loop diuretics</td>
                  <td align="center">156/206 (75.7%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">Thiazide diuretics</td>
                  <td align="center">26/206 (12.6%)</td>
                </tr>
                <tr>
                  <td align="center" colspan="2" rowspan="2">Spironolactone</td>
                  <td align="center">88/124 (70.9%)</td>
                </tr>
                <tr>
                  <td align="center">Spironolactone contraindicated for 82/206 (39.8%)</td>
                </tr>
                <tr>
                  <td colspan="2" rowspan="3">Clinical data on discharge*</td>
                  <td align="center" colspan="2">SBP, mmHg &#8211; md (IQR)</td>
                  <td align="center">107.1 &#177; 18.5</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">DBP, mmHg &#8211; md (IQR)</td>
                  <td align="center">67.3 &#177; 12.4</td>
                </tr>
                <tr>
                  <td align="center" colspan="2">HR, beats per minute &#8211; md (IQR)</td>
                  <td align="center">77.9 &#177; 14.2</td>
                </tr>
                <tr>
                  <td>Instructions</td>
                  <td align="center" rowspan="4">Smoking cessation<sup>&#8224;</sup></td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">10/27 (37.0%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">No</td>
                  <td align="center">17/27 (63.0%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">Non-applicable</td>
                  <td align="center">180/207 (87.0%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">0/27 (0.0%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" rowspan="3">Weight control</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">122/207 (58.9%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">No</td>
                  <td align="center">8/207 (3.9%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">77/207 (37.2%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" rowspan="3">Physical exercise</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">119/206 (57.8%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">No</td>
                  <td align="center">16/206 (7.8%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">Non-applicable</td>
                  <td align="center">71/206 (34.5%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" rowspan="4">Referred for rehabilitation<sup>&#8224;</sup></td>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">138/196 (70.4%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">5/196 (2.6%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">No</td>
                  <td align="center">11/207 (5.3%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">53/196 (27.0%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" rowspan="3">Use of prescribed medications</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">180/206 (87.4%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">No</td>
                  <td align="center">0/206 (0.0%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">Non-applicable</td>
                  <td align="center">26/206 (12.6%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" rowspan="3">Counseling in case of worsening of symptoms</td>
                  <td align="center" colspan="2">Yes</td>
                  <td align="center">141/206 (68.4%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">No</td>
                  <td align="center">3/206 (1.4%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2">Not documented</td>
                  <td align="center">62/206 (30.1%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2" rowspan="3">Vaccination counseling (Influenza and Pneumococcal)</td>
                  <td align="center">Yes</td>
                  <td align="center">57/207 (27.5%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center">No</td>
                  <td align="center">21/207 (10.1%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center">Not documented</td>
                  <td align="center">129/207 (62.3%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2" rowspan="3">Outpatient follow-up</td>
                  <td align="center">Yes</td>
                  <td align="center">202/207 (97.6%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center">No</td>
                  <td align="center">5/207 (2.4%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center">Not documented</td>
                  <td align="center">4/207 (1.9%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center" colspan="2" rowspan="4">Anticoagulant therapy<sup>&#8224;</sup></td>
                  <td align="center">Yes</td>
                  <td align="center">53/63 (84.1%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center">No</td>
                  <td align="center">1/63 (1.6%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center">Non applicable</td>
                  <td align="center">77/140 (55.0%)</td>
                </tr>
                <tr>
                  <td> </td>
                  <td align="center">Not documented</td>
                  <td align="center">9/63 (14.3%)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN5001">
                <p>
                  <italic>BB: beta-blocker; ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blocker; HR: heart rate; DBP: diastolic blood pressure; SBP: systolic blood pressure. * Variables as median and 1st and 3rd quartiles [md (IQR)]. &#8224; Calculated based on patients to whom this therapy is indicated.</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p><xref ref-type="table" rid="t7001">Chart 1</xref> describes the performance indicators analyzed in the study. It is worth noting that the indicator &#8220;adequate reperfusion therapy (door-to-needle time and door-to-balloon time&#8221; was not evaluated, since public health users from the whole metropolitan area with the diagnosis of ACS can be referred for coronary angiography at the General Hospital, which made it difficult to determine these times. Adherence rates were above 85% for six of the seven indicators analyzed In the ACS arm and for only three of the five indicators in the HF arm. <xref ref-type="fig" rid="f01001">Central Illustration</xref> summarizes the main findings of the study.</p>
        <p>
          <table-wrap id="t7001">
            <label>Chart 1</label>
            <caption>
              <title>&#8211; Performance indicators on discharge</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" scope="col" style="font-weight:normal"> </th>
                  <th colspan="2" scope="col">Performance indicators</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="7">Acute coronary syndrome *</td>
                  <td align="center">Early aspirin use</td>
                  <td align="center">739/756 (99.1%)</td>
                </tr>
                <tr>
                  <td align="center">Aspirin at discharge</td>
                  <td align="center">700/733 (95.5%)</td>
                </tr>
                <tr>
                  <td align="center">ACEI or ARB at discharge</td>
                  <td align="center">581/635 (91.5%)</td>
                </tr>
                <tr>
                  <td align="center">Beta-blocker at discharge</td>
                  <td align="center">616/657 (93.7%)</td>
                </tr>
                <tr>
                  <td align="center">Statin at discharge</td>
                  <td align="center">707/733 (96.5%)</td>
                </tr>
                <tr>
                  <td align="center">Blood pressure control</td>
                  <td align="center">489/570 (85.8%)</td>
                </tr>
                <tr>
                  <td align="center">Tobacco cessation counseling</td>
                  <td align="center">277/340 (81.5%)</td>
                </tr>
                <tr>
                  <td rowspan="5">Heart failure</td>
                  <td align="center">Left ventricular function assessment</td>
                  <td align="center">242/243 (99.6%)</td>
                </tr>
                <tr>
                  <td align="center">ACEI or ARB at discharge</td>
                  <td align="center">120/145 (82.7%)</td>
                </tr>
                <tr>
                  <td align="center">Beta-blocker at discharge</td>
                  <td align="center">136/145 (93.8%)</td>
                </tr>
                <tr>
                  <td align="center">Spironolactone at discharge</td>
                  <td align="center">88/124 (70.9%)</td>
                </tr>
                <tr>
                  <td align="center">Post-discharge outpatient visit</td>
                  <td align="center">202/207 (97.6%)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN6001">
                <p>
                  <italic>ACEI: Angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blocker. The indicator &#8220;adequate reperfusion therapy&#8221; was not evaluated since this hospital is a referral center for primary angioplasty, and all patients of this sample already had the diagnosis of acute coronary syndrome when referred for this hospital.</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>
          <fig id="f01001">
            <label>Central Illustration</label>
            <caption>
              <title>: Cardiovascular Statistics from the Good Practices in Cardiology Program &#8211; Data from a Brazilian Tertiary Public Hospital</title>
            </caption>
            <attrib>
              <italic>HF: heart failure; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; SBC: Sociedade Brasileira de Cardiologia (Brazilian Society of Cardiology).</italic>
            </attrib>
            <graphic xlink:href="1678-4170-abc-120-02-e20220247-20247-gf01-en.tif"/></fig>
        </p>
      </sec>
      <sec sec-type="discussion">
        <title>Discussion</title>
        <p>Data of the present study characterize patients hospitalized for ACS and HF in a public tertiary hospital, which can provide all lines of treatment for cardiac patients who attend public health institutions. Although patients had a low income, high proportion of partial illiteracy, and highly complex conditions, it did not preclude an adequate adherence to evidence-based therapies established by the SBC, particularly in the system of care of ACS.</p>
        <p>In Brazil, the SBC led the construction of clinical registries of CVD, including the national registry of ACS (the ACCEPT registry).<sup><xref ref-type="bibr" rid="B7">7</xref></sup>Preliminary data indicate a high in-hospital mortality rate as well as low prescription rates of therapies proven effective in hospitalized patients. These data are in agreement with the BRACE (Brazilian Registry on Acute Coronary Syndromes).<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
        <p>As compared with the ACCEPT registry<sup><xref ref-type="bibr" rid="B7">7</xref></sup>and the BRACE,<sup><xref ref-type="bibr" rid="B8">8</xref></sup>hospitalized patients with ACS in the UFMG General Hospital are slightly younger, but do have a similar profile in terms of comorbidities, particularly high rates of hypertension, diabetes and smoking. However, two remarkable differences stand out &#8211; first, there was a predominance of AMI with ST segment elevation, as the general hospital is a referral center for primary angioplasty; second, the performance indicators analyzed in the ACS arm are quantitively better than those analyzed on patient discharge in the BRACE.</p>
        <p>Importantly, in the city of Belo Horizonte, aiming at improving the access of patients covered by the Brazilian Unified Health System to ACS treatment, a system of care for AMI was implemented between 2010 and 2011.<sup><xref ref-type="bibr" rid="B13">13</xref></sup>In this regard, the active participation of the general hospital has always stood out by the involvement of its telehealth center, coronary unit, division of cardiovascular surgery, cardiovascular hemodynamics, ward beds dedicated to these patients, in addition to the outpatient center for post-discharge follow-up care. Therefore, this system of care had already been monitored in the hospital and, based on previously published data,<sup><xref ref-type="bibr" rid="B14">14</xref></sup>the continuing education process has allowed the results of the performance indicators to be presented in the current study.</p>
        <p>Another national registry, also held by the SBC, is the BREATHE,<sup><xref ref-type="bibr" rid="B9">9</xref></sup>of the system of care for HF, which similarly to ACS, has reported a low prescription rate of medications based on the best evidence for this disease. When data of the present study are compared with those of the BREATHE registry, patients of the UFMG General Hospital are different in terms of the main etiologies of HF and higher clinical complexity. This is characterized by the presence of many patients assessed for eligibility or referred for cardiac transplantation, by the frequent use of inotropes and vasodilators, and high in-hospital mortality rates. Analysis of the performance indicators in this arm indicates the need for improvements in discharge prescription and in the instructions to patients with HF.</p>
        <p>Following the world trend, public health costs have increased in Brazil,<sup><xref ref-type="bibr" rid="B15">15</xref></sup>and a series of initiatives to improve system efficacy, particularly those aiming at improving the quality of care provided to patients with CVD can be implemented.<sup><xref ref-type="bibr" rid="B16">16</xref></sup>Based on this, the SBC created the GPC program<sup><xref ref-type="bibr" rid="B11">11</xref></sup>and the UFMG General Hospital implemented this program in our institution. In the same line, projects including text messaging by cell phone to improve the control of cardiovascular risk factors after discharge were also developed in the hospital.<sup><xref ref-type="bibr" rid="B17">17</xref> , <xref ref-type="bibr" rid="B18">18</xref> </sup>Data of the GWTG program are robust and show that adherence to the guidelines have drastically increased over time,<sup><xref ref-type="bibr" rid="B19">19</xref></sup>resulting in clinical benefits to the patients seen in the institutions participants of this program in the United States.<sup><xref ref-type="bibr" rid="B20">20</xref></sup>The SBC is engaged in providing the best care possible to all patients with CVD in Brazil.</p>
        <p>Data of the GPC program carried out in the UFMG General Hospital described in the present study have important limitations. First, the number of missing data of some variables was high, which may have influenced the analysis of results. Second, since this study required the consent of the patient or a family member, in-hospital mortality may be underestimated, since patients with severe clinical conditions that had died before the consent form was signed may have not been included in the sample. Third, data collection could not have been consecutive during the whole period of analysis, either because of problems related to the staff involved in the GPC program or because of short periods of program interruption in the country. Finally, results of 30-day or six-month follow-up after discharge could not be presented due to the high amount of incomplete data.</p>
        <p>However, the presentation of nationwide, reliable and comprehensive data on CVD is a must to overcome inequalities and to provide the best care for cardiovascular disease patients. This study summarizes important information on ACS and HF in patients hospitalized in a public tertiary hospital in Brazil and helps to fill a knowledge gap in the literature about the subject, an important step in the planning of health politics in Brazil.</p>
      </sec>
      <sec sec-type="conclusions">
        <title>Conclusion</title>
        <p>The adherence to quality programs like the GPC program is crucial to improve care for patients hospitalized for ACS and HF. Analysis of the performance indicators revealed a good adherence to the SBC guidelines, particularly to those in the system of care for ACS.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <p>Study Association</p>
          <p>This study is not associated with any thesis or dissertation work.</p>
        </fn>
      </fn-group>
      <fn-group>
        <fn fn-type="financial-disclosure" id="fn7001">
          <p>Sources of Funding: This study was partially funded by PROADI-SUS and American Heart Association. Dr Ribeiro is supported in part by CNPq (310790/2021-2 and 465518/2014-1) and by FAPEMIG (PPM-00428-17 and RED-00081-16).</p>
        </fn>
      </fn-group>
      <fn-group>
        <fn fn-type="other">
          <p>
            <bold>Erratum</bold>
          </p>
          <p>Arq Bras Cardiol. 2023; 120(2):e20220247</p>
          <p>In the Original Article &#8220;Cardiovascular Statistics from the Good Practices in Cardiology Program &#8211; Data from a Brazilian Tertiary Public Hospital&#8221;, with DOI: https://doi.org/10.36660/abc.20220247, published in the journal Arquivos Brasileiros de Cardiologia, Arq Bras Cardiol. 2023; 120(2)e20220247, on page 1, correct the author&#8217;s name: Carolina Teixeira Cunha &#201;rika for: Carolina Teixeira Cunha.</p>
          <p>On page 10 correct reference 18 to: Passaglia LG, Brant LCC, Silva JLP, Nascimento BR, Ribeiro ALP. Text Messages to Promote Secondary Prevention after Acute Coronary Syndrome (IMPACS trial). Int J Cardiovasc Sci. 2021;35(2):202-13. doi:10.36660/ijcs.20200378.</p>
        </fn>
      </fn-group>
      <app-group>
        <app id="app1">
          <title>* Supplemental Materials</title>
          <p>For additional information Supplemental Material 1, please <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-1.pdf">click here</ext-link> .</p>
          <p>For additional information Supplemental Material 2, please <ext-link ext-link-type="uri" xlink:href="https://abccardiol.org/supplementary-material/2023/12002/2022-0247-suplemento-2.pdf">click here</ext-link> .</p>
        </app>
      </app-group>
    </back>
  </sub-article>
</article>
